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Abstract
Machine learning (ML) techniques have been widely applied in a variety of areas ranging
from pattern recognition, natural language processing, and computer games to self-driving
cars, clinical diagnostics, and molecular structure prediction easing day to day life of human
beings. Drug discovery is an expensive, complex, and time taking process. Currently, the
pharma industry is hoping to leverage machine learning methods in expediting the drug
discovery process. Molecular property prediction is one of the most important tasks in
drug discovery. While developing a new drug relies on a proper understanding of molecular properties, there has been great interest in the potential of machine learning models to predict molecular properties. In this dissertation, I have benchmarked several ML
algorithms against a variety of drug discovery related property predictions. More specifically, a comparison of several widely used ML algorithms with advanced ML algorithms
such as Direct Message Passing Neural Network (D-MPNN) is discussed in various molecular property prediction models. The traditional ML models are trained on computed
molecular fingerprints whereas D-MPNN is a graph-based neural network that learns by
operating on the graph structure of the molecule. The work presented in this dissertation is available as free and user-friendly computational tools that cover a wide range
of biochemical tasks such as binding affinity calculation, drug-target activity prediction
and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties
prediction. They can be accessed online via webservers (https://drugdiscovery.utep.edu)
and (https://drugcentral.org/). The source code and datasets are available in GitHub
(https://github.com/sirimullalab) for interested computational scientists to further validate and benchmark new algorithms.
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Chapter 1
Introduction
This chapter discusses the research background, research objectives, and machine learning
methodologies that were implemented during the research.

1.1

Machine Learning in Drug Discovery

Drug development is the process of finding a potential compound and bringing the new
candidate medication into the market. The major stages of drug discovery process include
target selection, compound screening, and lead optimization [1]. Because of increasing
costs, time and complexity, the drug development process has become challenging over the
years. A variety of risk factors associated with the drug development process not only
delays a new drug entering into the market but also increases the chance of failure. Thus,
ensuring drug safety is one of the main challenges in the drug discovery process. Interpreting information of the known effects of drugs and predicting their side effects are complex
tasks. Modern artificial intelligence (AI) combined with various experimental techniques
are expected to help in the drug development process. AI frameworks may contain several
different machine learning (ML) methods applied together. ML can automate many of the
processes utilizing a large amount of data that has been collected over a decade in various
fields of modern science and technology. For example, an unprecedented amount of drug
and protein data can be used in drug-target networks. The availability of a large amount
of data has supported the utilization of current AI procedures such as Deep Learning (DL)
algorithms and picked up immense accomplishment in a wide scope of uses, for example,
self-driving cars, computer games, speech recognition, natural language processing among
1

other applications. The drug development process can also be benefitted from incorporating AI in different areas [2]: (i) AI for Primary Drug Screening, that deals with sorting
and classification of cells by Image Analysis (ii) AI in Secondary Drug Screening (Prediction of Physical Properties, predictions of bioactivity, prediction of toxicity), (iii) AI in
Drug Design (Predicting the 3D structure of a Target Protein, Predicting Drug-Protein
Interactions), (iv) Planning Chemical Synthesis with AI (Retrosynthesis Pathway Prediction, Reaction Yield Prediction and Insights into Reaction Mechanism) (v) Automation
of Chemical Synthesis with AI (Digitization and Standardization of Synthesis, Automated
Sampling of Reaction Space with AI). Recently developed AI methods and tools can reduce
computational cost and time of these processes. One of the examples is an application of
ML in drug screening. Initial screening of compounds based on traditional high throughput
screening (HTS) libraries may take several months and cost millions of dollars as even a
screening of single compound costs 50-100 dollars [2]. This process can be shortened to
some days or months when AI-based computational tools are leveraged. For example, these
tools can aid in the identification of binding cavities which are crucial for structure-based
drug design [3]. The structure of a target protein can be determined experimentally, using
traditional methods, for example, nuclear magnetic resonance, X-ray crystallography, but
these methods are time consuming and labor-intensive tasks. Recent development of AIbased tools for the protein-structure prediction has shown promising results. AlphaFold,
built using vast genomic data has predicted the structure of protein amazingly well [4]. In
the work leading up to this dissertation, the author has worked on building the computational tools for drug target interactions and ADME properties. Such tools are able to
anticipate the various physicochemical characteristics, pharmacokinetics, safety and efficacy profiles, and binary predictions such as active or inactive of a query compound for its
target protein. for the corresponding target protein.

2

Figure 1.1: Illustration of a general workflow for machine learning model development in
molecular property prediction projects

1.1.1

Drug Target Interaction

Drug Target Interaction (DTI) plays a pivotal role in the drug discovery, drug repurposing,
and drug side effect predictions [5]. It narrows down the searching of chemical space
by suggesting potential DTI candidates. A drug is a chemical compound which brings
the physiological change in the human body and target refers to the cellular structure
or molecular structure in living organisms involved in the pathology of interest. When a
drug binds to a target, it creates a positive or negative change before leaving the target.
A drug that inhibits the activity of the target in the human body in order to treat the
disease is known as an inhibitor. In-silico prediction of drug-target interaction assists
with recognizing to new drugs that bind to targets. The computational techniques for
DTIs predictions can be characterized into three classes: ligand based approaches, docking
approaches and chemogenomic approaches [6]. The ligand-based approach uses the concepts
that the differences in chemical molecular structures cause the different bioactivities. The

3

molecular fingerprints obtained from the small molecules can be compared with each other
for known protein targets. The more similar the fingerprint vectors of molecules, the
more likely they bind to similar proteins. In this way, the ligand-based approach leverages
the concept that comparable atoms tend to share comparable properties and share same
target proteins [7]. The computational cost is generally low and high predictivity in some
well-studied targets, but there are some disadvantages of ligand-based approaches. As
the protein information is not used for prediction, it is unlikely to have the prediction of
novel protein and drug pairs. In docking approaches, the simulation of 3D structures of
the drug and protein identifies whether they would interact [8]. High resolution details
of the structures can be helpful for the prediction of new targets. However, this method
also suffers from certain drawbacks: high computational cost, scalability is limited by
structural coverage, and more importantly not all proteins have known 3D structures and
thus prediction of such proteins is a challenging task. In chemogenomic approaches, the
information of both a drug and a protein are used for the prediction of DTIs. Thus, this
approach overcomes the drawbacks of ligand based and docking based methods.
Identifying drug-target relationships may expose secret drug or protein functions and
shed light on the mechanisms of mysterious disease pathology [9]. It provides scientists with
observations that help to predict adverse drug effects. In addition, DTI prediction can also
exploit drug repositioning, which seeks to uncover potential applications for already licensed
medicines, in addition to finding new drugs. However, despite the scientific community’s
ongoing efforts, the laboratory detection of DTIs remains highly challenging in terms of
both time and expenditure. The use of computer techniques and in particular, in-silico
DTI prediction for machine learning is thus crucial for drug discovery and repositioning.
In large-scale drug or protein data sets, machine learning models can direct experiments,
uncover latent patterns and extract unparalleled information from drug-target networks.
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1.1.2

Drug Repurposing

Drug discovery consists of two strategies: conventional drug development and drug repurposing. As James Black, the pharmacologist and Nobel laureate, said, “the most fruitful
basis for the discovery of a new drug is to start with an old drug”. Since the development
process of new medication is time consuming and expensive, finding the new indications
of existing drugs, which is known as drug repurposing or repositioning [10], can play a
significant role to shorten the development cycle. Compared to traditional drug development approaches, it has fewer phases, which are: compound identification, compound
acquisition, clinical testing, and FDA post-market safety monitoring. In addition to lower
computational cost and time, drug repurposing has several benefits. Because the safety
and valuable information pertaining to drug metabolism and pharmacokinetic properties
are already known, repurposing known drugs can bring medications to patients much faster
and with less cost than that of developing new drugs. It is estimated that 30% of newly
approved FDA drug products and vaccines have been repurposed [11]. The premise behind the repurposing of drugs is that several different diseases are triggered by common
molecular pathways. In phase II clinical trials, which usually last two years and cost $17
million [12, 13], any newly discovered use can be rapidly tested. Computational methods
that directly predict drug-side effect or drug-disease associations are useful tools for drug
repurposing. As COVID-19 cases and deaths are rising daily, biopharmaceutical companies are in desperate need to accelerate the entire drug development process. In these
circumstances, AI technologies enable businesses to dramatically shorten the process of
discovering and developing pre-clinical drugs from several years to a few days or months.
The COVID-19 epidemic has caused chaos, and a clinical drug that has a history of use
in patients to overcome the current pandemic would be a simple cure for the disease. AIenabled drug repurposing will prove beneficial in the COVID-19 scenario with technical
developments in Artificial Intelligence (AI) coupled with enhanced computational capacity. In this sense, new promising effects against COVID-19 in vitro were discovered by the
antiviral drug Remdesivir mainly used in the treatment of Ebola virus clinical trials [14].
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Similarly, in the treatment of viral infection, Chloroquine (CQ) and its hydroxyl analog
Hydroxychloroquine (HCQ) have been recorded [14].

1.1.3

Drug Metabolism and PharmacoKinetic Properties

The assessment of drug metabolic and pharmacokinetic (DMPK) properties, toxicity (T),
and potency is crucial to achieving the desired biological activities and determining the
safety profiles of drugs. A compound’s DMPK profile describes the properties of absorption,
dissemination, metabolism and excretion (ADME). In the early stages of drug production,
the key goal of preclinical ADME is to remove poor drug candidates, allowing resources
to be concentrated on promising drug candidates. Traditionally, these properties were
determined at the end of drug discovery pipeline, but now they can be predicted due
to available computational tools at the early stage of the drug discovery process. At an
early point, prediction of such properties greatly decreased the number of compounds that
failed in later phases due to weak ADMET properties [15]. The absorption, distribution,
metabolism, excretion, and toxicity are summarized as follows:
Absorption: Absorption is the method of entering the drug into the bloodstream from the
point of administration. Intravenous and oral are the most common drug routes, although
there are different potential routes of administration. “Intravenous” means “into the vein”,
meaning that the drug is sent directly through a needle or tube into the vein. Many medications are orally dosed because of ease of administration, controllable delivery, viability for
solid formulations, patient compliance, etc. Many variables, including molecular weight,
topological polar surface area (TPSA), solubility, ionization, and other physicochemical
properties, will affect the absorption of a drug. Importantly, information on absorption
can be useful in assessing the propensity for how much of the medication following oral
administration enters the bloodstream. The first-pass effect after oral absorption (among
other factors) will eventually affect bioavailability.
Distribution: After administration of a drug into the bloodstream, either by intravascular
injection or by absorption from any one of the extracellular sites, it moves from absorption
6

site to tissues around the body. Normally, distribution happens across the bloodstream, but
it may also take place from cell to cell. Regional blood flow patterns, molecular polarity,
molecular size, and binding to serum proteins are some of the factors that can influence drug
delivery. In general, there are four main methods of crossing biological lipid membranes by
small molecules: passive diffusion, filtration, special transport, and endocytosis.
Metabolism: Metabolism refers to the molecular alterations of drugs that make it possible to excrete them. More lipophilic xenobiotic compounds are generally converted into
hydrophilic metabolites that can be removed by excretion from the body. Compounds tend
to break down in the body through the Cytochrome P450 mechanism, a family of enzymes
in the liver. Drugs are made more polar by oxidation-reduction reactions or hydrolysis
in phase I reaction. In order to catalyze biotransformation, these reactions use metabolic
enzymes, most commonly those from the cytochrome P450 enzyme system. Conjugation,
or phase II, reactions include the second form of metabolism. The drug undergoing the
transition is mixed with another product in this form of reaction, such as glucuronic acid,
sulfuric acid, acetic acid, or amino acid. The product of conjugation is a more watersoluble substance that can be excreted more quickly by the kidneys. And commonly, these
metabolites are therapeutically inert.
Excretion: The mechanism by which the metabolized drug substance is removed from the
body is excretion. The bulk of excretion happens as urine from the kidneys or as feces.
Excretion relies on the kidney filtration mechanism at the glomerulus which is primarily
dependent on the size and charge of the molecules. Some molecules may be excreted as
sweat through the skin and some can also be excreted through gas exchange through the
lungs. The molecule or metabolic by-product can bioaccumulate and adversely impact
living systems if excretion is not a complete process. If a substance is lipid-soluble, it will
bioaccumulate more quickly in adipose tissue.
Toxicity: Toxicity is the degree to which an individual or substructures such as cells
and organs of the organism may be affected by a product. It is responsible for several
compounds at the late stage of drug production and once approved, for the removal from
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the market of a significant number of compounds. Nearly 20-40% of drug failures are due
to questions about toxicity. Mechanisms of toxicity can be divided into several groups,
such as toxicity caused by pharmacophores, toxicity linked to structures, toxicity induced
by metabolism, etc.

1.2

Research Objectives

Given that there are diverse and heterogeneous types of information available on drug
activity contributing to drug target interactions, drug metabolism and pharmacokinetic
properties, it is essential to integrate and leverage all this information and build in silico
models that can accurately predict the drug activities. There are various computational
packages, but most of them are focused on one specific property or model only, and most
of them are commercial softwares. Thus, in this dissertation, I accomplished the following
specific tasks to provide free and user friendly computational tools that can be used in drug
discovery research.
• Compare different machine learning methods: To obtain the state-of-art machine learning model that can accurately predict the various properties of drug or
drug like molecules, I leveraged a list of ML algorithms available in scikit-learn and
investigated their performance on different sets of data from drug activities, drug
metabolism, and pharmacokinetic properties. Also, the performance of ML models
trained on computed molecular fingerprints were compared with the models trained
on the on graph structure of the molecule.
• Deployment of ML models: The best performing models were then turned
into Application Programming Interfaces (APIs) and were already available
in user friendly web interfaces.

They can be accessed online via web-

servers (https://drugdiscovery.utep.edu) and https://drugcentral.org/. The source
code and data for some of the tools are available in GitHub repository
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(https://github.com/sirimullalab) for interested computational scientists to further
validate and benchmark new algorithms.

1.3

Machine Learning

Machine learning, a branch of artificial intelligence developed on the idea that a system
learns from the data, looks for the patterns and make decisions with minimal human intervention. The availability of large datasets, improved algorithms, and increased computing
resources have contributed to unprecedented surge of interest in the field of machine learning. There are many applications of machine learning ranging from information retrieval,
speech recognition, and customer support to computer games, self-driving cars, and clinical diagnostics. It has tremendously reduced the time and expenses of the people in the
modern world. Machine learning is broadly categorized into two methods: unsupervised
learning and supervised learning.

1.3.1

Unsupervised Learning Method

Unsupervised learning is the training of machine using data that is neither categorized nor
labelled and enables the algorithm to operate without guidance on that data. It can be
used to find hidden structure in unlabeled data. As such, there aren’t necessarily defined
outcomes from unsupervised learning algorithms. Rather, it determines what is different
or interesting from the given dataset. In general, this method is used for exploratory
data analysis to discover the patterns, clusters, to reduce the dimension of the data, and
to remove the outliers. Clustering and anomaly detection are some of the examples of
unsupervised learning.
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1.3.2

Supervised Learning Method

In this method, data sets used has the associated outcome yi for each data point xi such
that machine learns from the association between the xi and yi . For example, given features
(such as size, color, and shape) of a particular fruit and its name (such as apple), machine
gets trained using the known information and capable of predicting new data to the correct
classes. Data is normally divided into training and test sets. The training data is used to
train the underlying algorithm. The test set is then fed on trained algorithm to assess its
performance . Sometimes, a validation set is also used to select the best performer of a
collection of models.
The following methods are the most common machine learning methods that are used
in our project.
1.3.2.1

Artificial Neural Network

Artificial neural networks (ANN) [16] are brain-inspired systems that can detect patterns in
data by imitating the activity of the brain, and then extrapolate predictions when new data
is supplied. ANN consists of at least three separate layers, as seen in the Figure 1.2: input
layer, hidden layer and output layer. Each layer of neurons and each neuron performs a
series of mathematical operations in order to turn its input into its output. The input layer
is the input signal layer and is responsible for the initial calculations. The computed values
are moved to subsequent ANN layers. These layers could be a single layer or several layers
that are concealed. In the last hidden layer, the outputs from the neurons are transferred
to the neuron or neurons that produce the net’s final outputs.
ANN was used in KinasepKipred (chapter 4). We used “ReLU” as an activation function, “mean squared error” as a loss function, and “adam” as an optimizer. The learning
was completed in 100 epochs with a batch size of 25.
Activation functions: The activation functions are crucial components in ANN as they
play important role to determine the output of the trained model, its accuracy and also the

10

computational efficiency of the model. They make a major effect on the neural networks’
ability to converge and also help normalize the output of each neuron to a range between
0 and 1 or between -1 and 1. The output of a neural network unit is a biased linear
combination of its input values xi followed by a nonlinear activation function f.
A=f

X



wi xi + b ,

(1.1)

i

where wi are learned weights and b is a learned bias The most commonly used activation
functions are rectified linear unit (ReLU), sigmoid, and tanh as shown in figure below.

Figure 1.2: Artificial Neural Net-

Figure 1.3: Commonly used activa-

work

tion functions

1.3.2.2

Gradient Boosting

Gradient Boosting (GB) algorithms was initially introduced by Breiman [17] builds a strong
prediction model by ensemble of weak predictions models, where decision trees are typically
used. It was designed for classification problemes but later Friedman extended for the regression problems and named as gradient boosting machine learning methods (GBM) [18].
This method constructs a forward stage-wise additive model by integrating decent optimization in function space. The GBM algorithm iteratively adds at each step a new decision
tree that best reduces the loss function. The initial parametrization in terms of gradient
at stage n can be written as:


∂L(y, f(x))
– gn (x) =
∂f(x)
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wheref(x) = f n–1 (x)

(1.2)

and a squared error used as a loss function for the gradient,
φn = argminφ

k
X

[(–gn (xi ) – φ(xi ))]2 ,

(1.3)

i=1

where φn is the gradient loss at iteration n and φ is the current gradient estimate for xi .
The equation for line search can be written as:
ρn = argminρ

k
X

L(yi f (n–1) (xi ) + ρφn (xi )),

(1.4)

i=1

where ρn defines the step taken a stage n. The function that has to be optimized at each
step along with a shrinkage parameter η ∈ (0, 1] is written as:
f N (x)

f(x) =

=

N
X

f n (x) = f 0 (x) +

n=0

N
X

ηρn φn (x)

(1.5)

n=1

Initialize f 0 for a single decision tree model and thus can be defined as:
f 0 (x) = argminθ

k
X

L(yi , θ)

(1.6)

i=1

Now the modified loss function in terms of gradient is written as:

L(φn ) =

=

=

Pn
X

[(–gn (xi ) – φn (xi ))]2

i=1
k
h
i
X
2
2
gn + 2gn (xi ) + φm (xi )
i=1



(1.7)


X


j=1

k
X

g2n (xi ) + 2wjn

i∈Qnj

X

gn (xi ) + mjn w2jn  ,

i∈Qnj

where mjn is the total number of points in a regioin j.
Pn h
i
X
L(φn ) =
2Gjn wjn + mjn w2jn + C,

(1.8)

j=1

Gjn
for j ∈ 1, ...Pn are the weights that minimizes the
where C is a constant and wjn = –
njn
loss function.
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Finally, the Gain (G) of the split can be obtained as:
G=

G2jnL
njnL

+

G2jnP
njnP

–

G2jn
njn

(1.9)

In our work, GB was used in redial-2020 (chapter 2) and tuning was performed on
“number of estimators” and “learning rate”.
1.3.2.3

Extreme Gradient Boosting

Extreme Gradient Boosting (XGBoost) algorithm is an advanced version of gradient boosting, which gives better performance in less computational time. It was introduced to the
Distributed Machine Learning Community (DMLC) group by Chen [19] and has been used
as a award wining algorithms for many competitions, thus becoming more popular in recent
years. The XGBoost solves for the gradient step directly for each x in the data set unlike
GB such that:

∂L(y, f (n–1) (x) + f n (x))
= 0,
∂f n (x)

(1.10)

which is derived from second order Taylor-series expansion around the gradient estimate
f (n–1) :
1
L(y, f (n–1) (x) + f n (x)) ≈ L(y, f (n–1) (x)) + gn (x)f n (x) + hn (x)f n (x),
2

(1.11)

where gn (x) and hn (x) are the gradient and the Hessian at the current estimate n respectively. The Hessian can be defined as:
hn (x) =

∂ 2 L(y, f (n–1) (x))
∂f (n–1) (x)2

(1.12)

The loss function can rewritten as:

n 
X
1
2
L(f n ) ≈
gn (xi )f n (xi ) + hn (xi )f n (xi ) + C
2
i=1


Pn 
X
1
2
∝
Gjn wjn + Hjn wjn ,
2
i=1
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(1.13)

where C is a constant, Gjn and Hjn are the sums of the gradient and Hessian in region j
respectively. For a fixed model structure, the loss function and weights can be rewritten as
follows:
L(φm ) =

Pn 
X
j=1


1
2
2Gjn wjn + Hjn wjn ,
2

Gjn
where wjn =
for j ∈ 1, ..., Tn .
Hjn
The Gain for each split with left (L) and right node (R) can be obtained as:
" 2
#
2
2
1 GjnL GjnR Gjn
G=
+
–
2 HjnL HjnR Hjn

(1.14)

(1.15)

In our work, XGBoost was used in redial-2020 (chapter 2) and tuning was performed
on “number of estimators” and “learning rate”.
1.3.2.4

Support Vector Machine

Support Vector Machine (SVM) [20] technique addresses a non-linear boundary between
classes by enlarging the feature space using quadratic, cubic, and higher-order polynomial
functions of the predictors [21]. SVM performs the classification by finding the hyperplane
that maximizes the margin. The margin is the distance between the two closest examples
from the opposite classes along the direction normal to the hyperplane. Given a training
vectors xi ∈ i = 1, ..., n in two classes, and a vector y ∈ {1, –1}n , in order to find w ∈ Rp
and b ∈ R, SVC solves the problem as:
n

X
1
min wT w + C
ζi
w,b,ζ 2

(1.16)

i=1

subject to
yi (wT φ(xi ) + b) ≥ 1 – ζi ,

(1.17)

ζi ≥ 0, i = 1, ..., n
The dual problem is:
1
min αT Qα – eT α
α 2
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(1.18)

subject to
yT α = 0
0 ≤ αi C,

(1.19)

i = 1, ...., n

where e is the vector containing only ones, C > 0 is the upper bound and Q is an n by n
positive semi-definite matrix. Q is written as:
Q ≡ yi yj K(xi , xj ),

(1.20)

where K(xi , xj ) = φ(xi )T φ(xj ) is the kernel.
The output of the decision function for a given sample x is given by:
n
X

sgn
yi αi K(xi , x) + b

(1.21)

i=1

1.3.2.5

Logistic Regression

Logistic regression is one of the widely used statistical models for making prediction and
multivariate analysis. For m samples and n features, the logistic regression is defined as:
h(x) = β1 x1 + β2 x2 + β3 x3 + .... + βn xn

(1.22)

where x1 , x2 , x3 , ...., xn represent the input features and β1 , β2 , β3 , ...., βn are the regression
coefficients. The prediction probability of a query can be written as:
p(X) = P(Y = 1|X) =

exp(βT X)
,
1 + exp(βT X)

(1.23)

For the multinomial model with K classes and Y outcomes, the above equation can be
extended as follows:

exp(βT
K X)
P(Y = K|X) =
,
PK
1 + j=1 exp(βT
j X)

(1.24)

Regularization in Logistic regression plays important role in reducing the overfitting and
can be implemented with a λ parameter which is directly proportional to the penalty of
overfitted models. The cost function in logistic regression represents the total error of the
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model which is the difference between the actual and the predicted values. Cost function
for a single data point can be defined as:
1
Cost(ŷ, y) = (φ(βT X) – y)2
2

(1.25)

Thus, total cost function for the traning set is:
m

1 X
Cost(ŷ, y)
J(β) =
m

(1.26)

i=1

In this work, LR was used mainly in REDIAL-2020 (chapter 2) and model was tuned
using hyperparameters such as “penalty”, “C”, and “solver”.
1.3.2.6

Multilayer Perceptron

Multilayer Perceptron (MLP) is a supervised learning algorithm that learns a function
f(.) : Rm –→ R0 using traning dataset, where m is the number of dimensions for input and
0 is the number of dimensions for output. For a given set of features X = x1 , x2 , ..., xm and
target y, it learns a non-linear function approximator for either classification or regression.
It contains input layer, hidden layer(s), and output layer. The input layer consists of
a set of neurons {xi |x1 , x2 , ..., xm } for the input features. Each neuron in the hidden
layer transforms the values from the previous layer with a weighted linear summation
w1 x1 + w2 x2 + .... + wm xm followed by a non-linear activation function g(.) : R –→ R
such as logistic sigmoid function, no-op activation, and hyperbolic tangent function. The
MLP has the capabilities of learning in real time. However, it is suffered with certain
disadvantages such as hidden layers have a non-convex loss function where there exists
more than one local minimum. Similarly, different random weight initialization can lead to
different validation accuracy.
In our work, several MLP parameter combinations were used to achieve the highest
accuracy. Nevertheless, while tuning the models, “hidden layer size” and “max-iter” were
found successful. In most cases, MLP has been found to outperform other ML algorithms.
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1.3.3

Random Forests

Random forest (RF) [22] is an ensemble of decision trees (DTs) working together to achieve
a prediction that is more precise and stable. With separate datasets with characteristics and
labels, each DT is trained. We can use decision trees to formulate predictors for each test
case based on this definition. While decision trees are simple to understand and intuitive,
their predictions, such as those based on logistic regression, are not as precise as for other
types of predictors. In addition, the structure of the tree is very sensitive to the data given.
This means that the resulting tree structure can have dramatic effects on minor changes
to the results. Random forests are used in order to mitigate this issue. The forest selects
the performance of getting the most “vote” for discrete outcome or for numerical outcome,
the sum of all trees in the forest. Averaging the trees allows us to decrease the variance
and also increase the overall consistency and ultimately prevents overfitting. Figure 1.4
below shows an illustration of the RF algorithm. RF was used in all of the projects and

Figure 1.4: An illustration of a Random forest
had promising results in many of the cases. After several tests of different parameters, it
was found that “n-estimators” and “max features” were successful in obtaining the best
performing model.
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1.3.4

Direct Message Passing Neural Network (D–MPNN)

The Direct Message Passing Neural Network (D-MPNN) [23] is a graph based neural network built on framework of MPNN by Glimer et. al [24]. An MPNN is a unified framework
to generalize several graph convolution neural network methods. The input to MPNN is an
undirected graph G with node features xv and bond features evw , where v and w are the
node indices. The framework consists of two phases: message passing phase and readout
phase. The message passing phase gathers the structural information of the graph and
readout phase uses that information of the graph to make predictions.
For each step t, hidden states htv and messages mtv associated with each vertex v, the
message update equations can be written as,
mt+1
=
v

X

Mt (htv , htw , evw )ht+1
= Ut (htv , mt+1
v
v ),

(1.27)

w∈N(v)

where N(v) is the set neighbors of v in Graph G. The DMPNN differs with MPNN in terms
of message passing through the network. DMPNN updates the information of the directed
bonds rather than the information of the atoms. Thus, for hidden states htvw and messages
mtvw of edges instead of nodes, the message passing update equations are as follows:
mt+1
vw =

X

t
t+1
Mt (xv , xk , htkv )ht+1
vw = Ut (hvw , mvw ),

(1.28)

k∈N(v)\w

1.4

Quality assessment of models

Proper evaluation of machine learning models is an essential step to ensure robust modeling
of drug activities. In general, models were evaluated via nested cross-validation, independent test sets, and external sets. Classification models output discrete values, whereas
regression models output continuous values. Thus, the evaluation metrics depend up on
the type of the model used for the study. Common metrics for classification models are
derived from the “confusion matrix” (CM), which is a table that is often used for the measurement of performance of classification model on a set of test data for which the true
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values are known. It provides numbers for true positives (TP), true negatives (TN), false
positives (FP), and false negatives (FN). There are several evaluation metrics as derivatives
of CM such as accuracy, sensitivity, specificity, positive predictive value, negative predictive
value, Matthews Correlation Coefficient (MCC), area under the receiver operating characteristic (ROC) curve (AUC), and so on. For the regression problems, the most commonly
used metrics to measure the correlation between true and predicted values are coefficient
of determination (R2 ), Pearson’s correlation coefficient (R), Spearman’s rank correlation
coefficient (ρ), and root mean squred error (RMSE). Choosing the appropriate metric is
also an important while evaluating the machine learning models. For example, a simple
classification accuracy is often subject to caveats due to imbalanced data. Although accuracy and F1 score are computed based on confusion matrices, these measures are not
reliable as they show overoptimistic inflated results for imbalanced data. Thus binary classification models are often measured with a ROC curve, which plots True Positive Rate
(TPR) against False Positive Rate (FPR) at various threshold values [25] and MCC which
produces a high score only if the prediction obtained good results in all of the fours categories of confusion matrix (i.e., TP, FP, TN, and FN) [26]. The aforementioned evaluation
metrics can be summarized as follows:

1.4.1

Classification ML Evaluation Metrics

Accuracy (ACC)
ACC =

TP + TN
,
TP + FP + TN + FN

(1.29)

where TP, TN, FP, and FN are true positive, true negative, false positive, and false negative
respectively. The score ranges from 0 to 1, where a random prediction has a score of 0 and
perfect prediction has a score of 1.
Area under the curve (AUC): The area under the receiver operating characteristic
(ROC) curve is generally adopted in binary classification problems. The ROC curve was
created by plotting the true positive rate (TPR; i.e., sensitivity) against the false positive
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rate (FPR; i.e., 1– specificity) for different cutoff points and the accuracy was measured in
terms of area under the curve.
TP
TP + FN
FP
FPR =
TN + FP

TPR =

(1.30)
(1.31)

An area of 1 (i.e. 100%) represents a perfect test; an area of 0.5 (i.e. 50%) represents
a random test.
F1 Score This is the harmonic mean of the recall and precision:
F1 = 2 ∗

(precision ∗ recall)
(precision + recall)

(1.32)

The F1 score is calculated as the weighted average of the precision and recall. Therefore,
both false positives and false negatives are considered. The F1 score is usually more useful
than accuracy in the case of uneven class distribution. On the other hand, accuracy works
best if false positives and false negatives have similar cost. If the cost of false positives and
false negatives are very different, it is better to look at both precision and recall. The F1
score reaches its best score at 1 and worst score at 0.
Cohen’s Kappa: Cohen’s Kappa [27] is a statistic that measures inter-rater agreement
for categorical items:
p – pe
(1.33)
κ= o
1 – pe
where po is the empirical probability of agreement on the label assigned to any sample
(the observed agreement ratio), and pe is the expected agreement when both annotators
assign labels randomly. Its value ranges from 0 to 1, where if the raters are in complete
agreement, then κ = 1. If there is no agreement among the raters other than what would
be expected by chance, then κ = 0.
Mathew Correlation Coefficient (MCC): It is calculated as follows:
MCC =

TP ∗ TN – FP ∗ FN
(TP + FP)(TP + FN)(TN + FP)(TN + FN)
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(1.34)

It is used for the performance assessment of binary classifications. It takes into account
true and false positives and negatives and is generally treated as a rational measurement
that can be used even though the classes are of very different sizes. In essence, the MCC is
a correlation coefficient between the binary classifications observed and predicted; a value
between -1 and +1 is produced. A coefficient of +1 is a perfect forecast, 0 is no different
than a random prediction and -1 is a disparity between prediction and observation.

1.4.2

Regression ML Evaluation Metrics

Mean Square Error (MSE): It determines our predictions’ average square error. With
each input, it calculates the square difference between the predictions and the target and
then averages those values. It can be acquired as:
N

1X
MSE =
(yi – ŷi )2
N

(1.35)

i=1

The lower the value, the better the model is. Because we square the individual predictionwise errors before summing them up, it is non-negative.
Root Mean Square Error(RMSE) This is just the sum of the root mean square error
derived from the squared root. The square root is introduced to make scale of the errors
to be the same as the scale of targets. So, it is written as:
v
u
N
u1 X
t
RMSE =
(yi – ŷi )2
N

(1.36)

i=1

Coefficient of Determination: The another way to evaluate the model is to measure
the coefficient of determination, which is written as R2 . Mathematical form of R-squared
is as follows:
R2 = 1 –

SSE
SST

(1.37)

Where SSE is the sum of squared errors of our regression model and SST is the sum of
squared errors of our baseline model. They are calculated as
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N

SSE =

1X
(yi – ŷi )2
N

(1.38)

i=1
N

1X
SST =
(yi – ȳi )2
N
i=1

respectively.
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(1.39)
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Chapter 2
REDIAL-2020: A suite of machine
learning models to estimate
Anti-SARS-CoV-2 activities
This chapter is adopted from: Govinda KC*, Giovanni Bocci*, Srijan Verma, Mahmudulla
Hassan, Jayme Holmes, Jeremy Yang, suman sirimulla, and Tudor I. Oprea.“REDIAL2020: A suite of machine learning models to estimate Anti-SARS-CoV-2 activities“. (*
equal contribution) (recently submitted to Nature Machine Intelligence)

Absract: Strategies for drug discovery and repositioning are an urgent need with respect to COVID-19. We developed ”REDIAL-2020”, a suite of machine learning models
for estimating small molecule activity from molecular structure, for a range of SARSCoV-2 related assays. Each classifier is based on three distinct types of descriptors (fingerprint, physicochemical, and pharmacophore) for parallel model development. These
models were trained using high throughput screening data from the NCATS COVID19
portal (https://opendata.ncats.nih.gov/covid19/index.html), with multiple categorical machine learning algorithms.

The “best models” are combined in an ensemble consen-

sus predictor that outperforms single models where external validation is available.
This suite of machine learning models is available through the DrugCentral web portal
(http://drugcentral.org/Redial). Acceptable input formats are: drug name, PubChem
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CID, or SMILES; the output is an estimate of anti-SARS-CoV-2 activities. The web application reports estimated activity across three areas (viral entry, viral replication, and
live virus infectivity) spanning six independent models, followed by a similarity search that
displays the most similar molecules to the query among experimentally determined data.
The ML models have 60% to 74% external predictivity, based on three separate datasets.
Complementing the NCATS COVID19 portal, REDIAL-2020 can serve as a rapid online
tool for identifying active molecules for COVID-19 treatment. The source code and specific models are available through Github (https://github.com/sirimullalab/redial-2020), or
via Docker Hub (https://hub.docker.com/r/sirimullalab/redial-2020) for users preferring a
containerized version.

2.1

Introduction

Currently, there is an urgent need to find drugs and effective treatment options for coronavirus disease 2019 (COVID-19). Here, we present a suite of machine learning (ML) models
termed “REDIAL-2020” that forecast activities for live viral infectivity, viral entry, and viral replication, specifically for SARS-CoV-2 (severe acute respiratory syndrome coronavirus
2). This application can serve the scientific community when prioritizing compounds for in
vitro screening and may ultimately accelerate the identification of novel drug candidates for
the COVID-19 treatment. REDIAL-2020 currently consists of six independently trained
ML models and includes a similarity/substructure search module that queries the underlying experimental dataset for similar compounds. These ML models were trained using
experimental data generated by the following assays: the SARS-CoV-2 cytopathic effect
(CPE) assay and its host cell cytotoxicity counterscreen; the Spike-ACE2 protein-protein
interaction (AlphaLISA) assay and its TruHit counterscreen, as well as an angiotensinconverting enzyme 2 (ACE2) enzymatic activity assay; and 3C-like (3CL) proteinase enzymatic activity assay. The assays represent three distinct categories: i) viral entry (CPE [1]
and host cell cytotoxicity counterscreen [2]); ii) viral replication (3CL enzymatic activ-
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ity); and iii) live virus infectivity (AlphaLISA, TruHit counterscreen, and ACE2 enzymatic
activity) [3], as described in the National Center for Advancing Translational Sciences
(NCATS) COVID-19 portal [4]. We retrieved these datasets from the NCATS COVID19
portal [5]. The NCATS team is committed to performing a range of COVID19-related
viral and host target assays, as well as analyzing the results [6]. These ML models are
integrated into a user-friendly web portal that allows input using three different formats: i)
drug name, both as International Nonproprietary Name, INNs (e.g., hydroxychloroquine)
or as trade name (e.g., Plaquenil); ii) PubChem CID [7], i.e., PubChem Compound ID
number (e.g., 3652 for hydroxychloroquine); or iii) using the chemical structure encoded
in the SMILES (Simplified Molecular-Input Line-Entry System) format [8], respectively.
The workflow and output, regardless of input format, is identical and described below.
Drug repositioning requires computational support [9], and data-driven decision making
offers a pragmatic approach to identifying optimal candidates while minimizing the risk of
failure. Since molecular properties and bioactivities can be described as a function of chemical structure, cheminformatics-based predictive models are becoming increasingly useful
in drug discovery and repositioning research. Specifically, anti-SARS-CoV-2 models based
on high throughput data could be used as a prioritization step when planning experiments,
particularly for large molecular libraries, thus decreasing the number of experiments and reducing downstream costs. REDIAL-2020 could serve such a purpose and help the scientific
community reduce the number of molecules before experimental tests for anti-SARS-CoV-2
activity. This suite of ML models can also be used via the command line for large scale
virtual screening. As more reliable data sets become available in the public domain, we
plan to tune the ML models further, add additional models based on SARS-CoV-2 assays,
and make these models available in future releases of REDIAL-2020.
Live Virus Infectivity Assays
The SARS-CoV-2 cytopathic effect (CPE) assay measures the ability of a compound to
reverse the cytopathic effect induced by the virus in Vero E6 host cells. As cell viability is
reduced by viral infection, the CPE assay measures the compound’s ability to restore cell
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function (cytoprotection). While this assay does not provide any information concerning
the mechanism of action, it can be used to screen for antiviral activity in a high-throughput
manner. However, there is the possibility that the compound itself may exhibit a certain
degree of cytotoxicity, which could also reduce cell viability. Since this confounds the
interpretation of CPE assay results, masking the cyto-protective activity, a counter-screen
to measure host (Vero E6) cell cytotoxicity is used to detect such compounds. Thus, a net,
positive result from the combined CPE assays consists of a compound showing a protective
effect but no cytotoxicity.
Viral Entry Assays
The Spike-ACE2 protein-protein interaction (AlphaLISA) assay measures a compound’s
ability to disrupt the interaction between the viral Spike protein and its human receptor
protein, ACE2 (angiotensin-converting enzyme type 2) [10]. The surface of the ACE2
protein is the primary host factor recognized and targeted by SARS-CoV-2 virions [11].
This binding event between the SARS-CoV-2 Spike protein and the host ACE2 protein
initiates binding of the viral capsid and leads to viral entry into host cells. Thus, disrupting
the Spike-ACE2 interaction is likely to reduce the ability of SARS-CoV-2 virions to infect
host cells. This assay has two counterscreens, as follows. The TruHit counterscreen is used
to determine false positives, i.e., compounds that interfere with the AlphaLISA readout in
a non-specific manner, or with assay signal generation and/or detection. It uses the biotinstreptavidin interaction (one of the strongest known non-covalent drug-protein interactions)
because other compounds are unlikely to disturb it. Consequently, any compound showing
interference with this interaction is most likely a false positive. Common interfering agents
are oxygen scavengers or molecules with spectral properties sensitive to the 600-700 nm
wavelengths used in AlphaLISA. The second counterscreen is an enzymatic assay that
measures human ACE2 inhibition to identify compounds that could potentially disrupt
endogenous enzyme function. ACE2 lowers blood pressure by catalyzing the hydrolysis
of angiotensin II (a vasoconstrictor peptide) into the vasodilator angiotensin (1-7) [12].
While blocking the Spike-ACE2 interaction may stop viral entry, drugs effective in this
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manner could cause unwanted side-effects by blocking the endogenous vasodilating function
of ACE2. Thus, the ACE2 assay serves to detect such eventualities and to de-risk such
off-target events.
Viral Replication Assays
Following entry into the host cell, the main SARS-CoV-2 replication enzyme is 3C-like
proteinase (3CL), also called “main protease” or Mpro [13], which cleaves the two SARSCoV-2 polyproteins into various proteins (e.g., RNA polymerases, helicases, and methyltransferases, etc.), which are essential to the viral life cycle. Since inhibiting the 3CL protein
disrupts the viral replication process, this makes 3CL an attractive drug target [14]. The
SARS-CoV-2 3CL biochemical assay measures compounds’ ability to inhibit recombinant
3CL cleavage of a fluorescently labeled peptide substrate.
Note on assays and models terminology. Throughout this paper, we refer to assay and
model names as follows: “CPE” for SARS-CoV-2 cytopathic effect, “cytotox” for host
cell cytotoxicity counterscreen, “AlphaLISA” for Spike-ACE2 protein-protein interaction,
“TruHit” for Spike-ACE2 protein-protein interaction counterscreen, “ACE2” for ACE2
enzymatic activity, “3CL” for 3CL enzymatic activity.

2.2

Results and Discussion

2.2.1

Preliminary Data Analysis

Prior to developing ML models, unsupervised learning should be used to evaluate the
data and seek patterns that might guide successive steps. Hence, upon definition of the
experimental categories (see Methods for details), we inspected the data using principal
component analysis (PCA) [15] and applied it using VolSurf+ [16] molecular descriptors.
For both CPE and cytotox, clusters emerge along the first principal component (PC1;
Figure 2.1). For CPE data, the majority of compounds showing high to moderate CPE
activity are grouped in the right-hand of Figure 2.1A.
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Figure 2.1: PCA scores plot of the molecules tested in NCATS SARS-CoV-2 experiments based on VolSurf+ descriptors. A) CPE compounds colored by CPE categories:
high/moderate activity in yellow and low activity in black; B) cytotoxic compounds colored by cytotoxicity categories: high/moderate cytotoxic in orange and low (not) cytotoxic
in black. C) AlphaLISA compounds colored by Spike-ACE2 interaction blockers categories:
high/moderate (strong) blockers in red and low (weak) blockers in black. D) TruHit compounds, colored by AlphaLISA readout interfering categories: high/moderate interfering
in cyan and low interfering in black. E) ACE2 compounds, colored by ACE2 inhibition
categories: high/moderate (strong) inhibitors in magenta and low (weak) inhibitors in
black.
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At the same time, compounds with high to moderate cytotoxicity are grouped in the righthand region of Figure 2.1B. By inspecting the loading score plot for VolSurf+ descriptors
that are likely to contribute to these patterns, we identified membrane permeability (estimated using logP, the logarithm of the octanol/water partition coefficient) and water
solubility (estimated using logS, the logarithm of the thermodynamic aqueous solubility)
as major contributors to the first latent variable (see Supporting Information Figure 2.9).
Compounds with low logP/high logS, clustered in the left-hand region of the score plot,
are less likely to be active in the CPE assay and more likely to be non-cytotoxic.
The distribution of actives was also visualized for AlphaLISA and TruHit compounds
in Figures 1C and 1D, respectively (see also Table 1). For the AlphaLISA assay, although
clustering is less pronounced with respect to CPE (Figure 1A), the right-hand part of the
plot does capture most of the high/moderate activity compounds. Such distribution of
actives in the right-hand region was not observed for ACE2 actives (Figure 1E). Thus,
permeability and solubility are not the major determinants of this ACE2 inhibition assay.
The results of this preliminary analysis can be used to filter input data prior to machine
learning. For example, the majority of the compounds placed on the left side of the Figure 1 PCA plot are inactive (exception for ACE2). Therefore, prior to developing the
ML models, we applied cutoff filters based on compounds calculated logP and logS using
ALOGPS [17] to every dataset except for ACE2. These filters help narrow the focus of
ML model development on features derived only from compounds for which simple property criteria (e.g., logP and logS) cannot be used to distinguish actives from inactives –
specifically, the right-hand regions in Figure 1. The initial number of compounds, after
data wrangling, was 4,954. Upon use of the logS and logP filters, each dataset was reduced
in size (Table 1). However, the fraction of active compounds excluded from the ACE2
dataset was quite high (34%). Hence, logP and logS filters were not applied for ACE2
inhibition, and the complete dataset was used for model development. For 3CL enzymatic
activity, data from NCATS was retrieved separately. The initial set contained 12,263 compounds. However, data wrangling identified 1,850 duplicate and 3,000 “inconclusive”
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entries, which were discarded. Additional entries were removed during the desalting and
physicochemical feature generation as VolSurf descriptors could not be computed for some
of the compounds. The final 3CL dataset contains 6,961 entries, with 222 active and 6,739
inactive compounds. Given that the fraction of active 3CL compounds filtered would have
been 30%, the logP/logS filters were not applied. There were no significant activity clusters
detected in the 3CL dataset via PCA-VolSurf+ (see Supporting Information Figure SI2).
With respect to actives vs. inactives, the six NCATS assays are highly unbalanced,
with a disproportionate ratio of active (few) compounds compared to inactive (many)
compounds. For example, there were 9 times more inactives than actives and 3 times
more non-cytotoxic compounds than cytotoxic compounds for the CPE and cytotoxicity
assays, respectively. Thus, in order to avoid over-training for the dominant category, each
model was derived using random selection wherein compounds from the majority class were
selected in equal proportion to those of the minority class. Our balanced dataset numbers
were as follows: 736 for CPE, 1,662 for cytotox, 1,260 for AlphaLISA, 1,668 for TruHit,
206 for ACE2 and 442 for 3CL.

2.2.2

Models Comparison and Selection

To evaluate anti-SARS-CoV-2 activities of novel chemicals, we implemented six predictive
models based on consensus methods. Of the two consensus methods (voting-based and
probability score-based) evaluated, the voting-based consensus model showed better performance (Figures 2.17, 2.18, 2.19, 2.20, 2.21 in Appendix). Thus, the voting-based method
is implemented in the REDIAL-2020 app. Consensus models were generated based on the
top three performing models trained on fingerprint, pharmacophore, and physicochemical
descriptors (see Methods section for details). First, we selected a fingerprint model from
an initial evaluation of 19 different fingerprint descriptor methods. This was combined
with a Topological Pharmacophore Atom Triplets Fingerprints (TPATF) model. Finally,
the rdkit or VolSurf+ descriptor-based model provided a third model, based on physicochemical properties. All these models were trained with 22 different classifiers available in
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scikit-learn [18]. Figures 2.2(a-d) summarizes the comparison between various features and
ML algorithms. Figures 2.2a and 2.2b compare the performance of each feature across 22
ML algorithms (classifiers) and 6 assays. Figures 2.2c and 2.2d compare the performance
of each classifier across 22 features and 6 assays. For example, the violin plot for the avalon
feature (Figure 2.2a) summarizes F1-scores from all 6 assays (and 22 classifiers). Among
descriptors, VolSurf+ and lfcfp6 outperformed others, whereas the gradient boost classifier
and the MLP (multilayer perceptron) classifier performed better among ML algorithms.

Figure 2.2: Comparison between the following, across the 6 assays: a) features for the
validation set; b) features for the test set; c) ML algorithms for validation; and d) ML
algorithms for the test set, respectively.

Two options for the consensus model were considered, based on the potential overlap between VolSurf+ and rdkit descriptors: fingerprint+TPATF+rdkit, and finger-
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print+TPATF+VolSurf, respectively. VolSurf+ descriptors outperformed rdkit in CPE
and TruHit, whilst rdkit outperformed VolSurf+ in cytotox, AlphaLISA, ACE2, and 3CL
based on the tested evaluation metrics such as Accuracy, F1-score, and AUC (see Supporting Information Figures SI13-SI18). However, the situation changed when considering
consensus models. Inclusion of VolSurf+ yielded better models for the AlphaLISA, TruHit,
and ACE2 voting-based consensus models, whereas including rdkit yielded better consensus models for the CPE, cytotox, and 3CL consensus assays. Figures SI3-SI8 show a
comparison of the best models from each feature category. Concerning the web portal, we
implemented consensus model predictions based on the rdkit descriptors, since RDKit is
open-source software that can be ported and dockerized without restrictions. Out of the six
ML models, four (CPE, cytotox, TruHit, and 3CL) were implemented as consensus models
with the rdkit descriptors, with the remaining two (AlphaLISA and ACE2) implemented
as rdkit descriptor-based only. Tables 2.1 and 2.2 summarize the evaluation scores and the
confusion matrices, respectively, for all models implemented in REDIAL-2020.
Table 2.1: Summary of the results of the best models
Validation set results

Test set results

Model
ACC F1

SEN

PREC AUC ACC F1

SEN

PREC AUC

CPE

0.794 0.794 0.794 0.795

0.794 0.725 0.725 0.726 0.727

0.725

cytotox

0.771 0.771 0.771 0.772

0.771 0.7

0.7

0.7

0.7

0.7

AlphaLISA 0.788 0.788 0.788 0.79

0.789 0.762 0.762 0.762 0.762

0.762

TruHit

0.762 0.762 0.762 0.762

0.762 0.727 0.727 0.727 0.727

0.727

ACE2

0.806 0.805 0.804 0.812

0.804 0.452 0.452 0.453 0.453

0.452

3CL

0.803 0.802 0.803 0.81

0.803 0.672 0.671 0.671 0.672

0.671

ACC, Accuracy; F1, F1 score; SEN, sensitivity; PREC, precision; AUC, area under the receiver
operating characteristic curve
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Table 2.2: Confusion matrix values for each “best” model
Validation set results Test set results
Model
TP TN FP FN

TP TN FP FN

CPE

39

42

9

12

35

39

12

16

cytotox

95

97

27

30

85

90

35

40

AlphaLISA 78

71

24

16

71

73

21

24

TruHit

93

96

28

31

92

89

35

33

ACE2

11

14

2

4

7

7

8

9

3CL

29

24

9

4

24

21

12

10

TP, true positives; TN, true negatives; FP, false positives; FN,
false negatives

2.2.3

Submission Webpage

By accessing REDIAL-2020 (http://drugcentral.org/Redial) from any web browser, including mobile devices, the submission page is displayed (Figure 4). The web server accepts
SMILES, drug names, or PubChem CIDs as input. The User Interface (UI) at the top of
the page allows users to navigate various options (Figure 4). The UI provides summary information about the six models, such as model type, which descriptor categories were used
for training, and the evaluation scores. The UI further depicts the processes of cleaning the
chemical structures (encoded as SMILES) prior to training the ML models. Input queries
such as drug name and PubChem CID are converted to SMILES prior to processing. Each
SMILES string input is subject to four different steps, namely, converting the SMILES into
canonical SMILES [19], removing salts (if included), neutralizing formal charges (except
permanent ones), and standardizing tautomers. REDIAL-2020 predicts the CPE, cytotox,
AlphaLISA, TruHit, ACE2, and 3CL of the given compounds. The workflow of operations
performed on the submitted query SMILES through the redial webapp are summarized in
Figure 3. Figure 5 shows an output panel example, which is loaded on the same web page.
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Figure 2.3: REDIAL-2020 prediction workflow.
REDIAL-2020 links directly to DrugCentral [20, 21] for approved drugs, and to PubChem
for chemicals (where available), enabling easy access to additional information about the
query molecule. Using REDIAL-2020 estimates, promising anti-SARS-CoV-2 compounds
would be as follows: a) active in the CPE assay and b) inactive in the cytotox assay; or
c) active in the AlphaLISA assay but d) inactive in the TruHit assay while e) not blocking
ACE2; or f) active in the 3CL assay; or any combination of the above three. A schematic
representation of the “best profile” that can be defined for a molecule, after running all the
prediction models, is depicted in Figure 2.6.

Figure 2.4: REDIAL-2020 submission page.
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2.2.4

Similarity Search

For each query molecule, a fingerprint-based Tanomoto [22] similarity search is conducted
against molecules included in the model input datasets. For reference, we have used datasets
from the NCATS COVID19 portal [5] for the similarity search. The top 10 similar molecules
to that of the query molecule, based on Tanimoto coefficient [23] scores, are displayed (see
Figure 5).
2.2.4.1

External Predictivity

To confirm the utility of our models, we collected three additional datasets from the literature and submitted these molecules (external to our training/test sets) as input for
prediction. First, we used a recently developed database for COVID-19 experiments [24]
to explore and download published in vitro COVID-19 bioactivity data for approved drugs
which was reported in various recent papers [13, 25–32]. After removing drugs already
included in the NCATS experiments, we identified 39 external drugs active in anti-SARSCoV-2 CPE assays (Supporting Information Table SI1). Out of 39 drugs, 24 were predicted
as active by at least two models and by the consensus model (Figure 2.7), and 15 drugs
were predicted as inactive. Among those predicted to be inactive, independent experiments
suggest they are weakly active. Specifically, bortezomib (S. Bradfute, personal communication), methotrexate, omeprazole, ouabain, and phenazopyridine (C. Jonsson, personal
communication) show below 30% cell survival when tested at 10 µM. An additional set
of six drugs from this list are undergoing testing in the Jonsson lab. The second external
CPE set was collected from a recently published screen that included 21 compounds from
the ReFRAME library [33] validated in dose response across multiple cell lines[32]. Out
of 21 most potent compounds, 19 were identified as an external set to our CPE model
(Supporting Information Table SI2). Among these 19 compounds, 14 ( 74%) were correctly
predicted by consensus models (17 by at least one model) as active. The third dataset of
3CL (Mpro) inhibitors, identified [13] 6 inhibitors: ebselen(0.67 µM), disulfiram(9.35 µM),
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Figure 2.5: Screenshot of the webpage displaying ML estimates and similarity results for a
query molecule
39

Figure 2.6: Schematic representation of the most desirable profile for anti-SARS-CoV-2
activities that can be observed via REDIAL-2020 predictions, based on the six assays of
interest.
tideglusib(1.55 µM), carmofur(1.82 µM), shikonin(15.75 µM) and PX-12(21.39µM), respectively. Among these 6 inhibitors, our consensus 3CL model predicted 4 of them as actives,
and all 6 of them as actives by at least one of the three 3CL ML models. The consensus
model predicts all potent (activity less than 2µM) compounds correctly inhibitors, namely
ebselen, tideglusib, and carmofur, respectively. Thus, the REDIAL-2020 suite of models
correctly predicts 60% of the external compounds for the CPE assay, 74% of the external compounds for the ReFRAME library [33] and 66.67% of the external compounds for
3CL inhibitors [13], respectively. Although these values appear to underestimate previous
model performance in the validation and external sets (see Table 3), it has been noted that
CPE experiments are affected by significant intra- and inter-experiment variability [24].
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Figure 2.7: Venn diagrams showing the distribution of external set predictions according
to the ML models for a) CPE, 14 actives; c) 3CL, 6 actives. See the text for details.
Hence, we cannot exclude the possibility that some of the experiments performed by other
laboratories are not directly comparable with results from the NCATS COVID19 portal[5].

2.3

Conclusion

Here, we described “REDIAL-2020”, an open-source, open-access, open-science application
for estimating anti-SARS-CoV-2 activities from molecular structure. By leveraging the recently available data from NCATS, we developed six categorical ML models: CPE, cytotox,
AlphaLISA, TruHit, ACE2, and 3CL. Input data from NCATS were used to train and validate multiple ML models using a variety of algorithms and features. The best performing
models, in terms of F1 scores and test set predictions, were exposed on the REDIAL-2020
portal. Furthermore, a similarity search against the input data is conducted for every
submitted molecule. The top 10 most similar molecules to the query molecule from the
existing COVID-19 databases, together with associated experimental data, are displayed.
This allows users to evaluate the confidence of the ML predictions. REDIAL-2020 provides
a fast and reliable way to screen novel compounds for anti-SARS-CoV-2 activities. These
would be compounds that block live virus infectivity (CPE active but not cytotoxic); or
compounds that block viral entry (blocking the Spike/ACE2 interaction while not interfering with the assay and lacking ACE2 inhibition properties); or compounds that block viral
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replication, by inhibiting 3CL (Mpro) protease; or a combination of the above, respectively.
REDIAL-2020 is available on Github and Dockerhub as well, and the command-line version supports large scale virtual screening purposes. Future developments of REDIAL-2020
could include additional ML models based on, e.g., newly released TMPRSS2 inhibition
assay [34] data from the NCATS COVID19 portal, and perhaps other assay data as they
become available in the public domain. We will continue to update and enhance the ML
models, and make these models available in future releases of REDIAL-2020.

2.4
2.4.1

Methods
Data

Data for the SARS-CoV-2 cytopathic effect (CPE), the Vero E6 (host cell) cytotoxicity
counterscreen, the Spike-ACE2 protein-protein interaction (AlphaLISA), TruHit (AlphaLISA counterscreen), ACE2 enzymatic inhibition conterscreen, and 3CL enzymatic inhibition were obtained from the NCATS COVID19 portal [4, 5]. Assay data were mapped
to DrugCentral2020 to retrieve DrugCentral IDs, SMILES strings, and drug names. The
experimental results from NCATS were mined to define activity and significance classes.
The procedure for data extraction, wrangling, and post-processing are detailed as follows.
2.4.1.1

Mining NCATS COVID19 Data

All operations described below were performed using the Knime [35] platform. NCATS data
associated with the aforementioned assays was downloaded from the COVID19 portal [4, 5].
The files contained over 23,000 compounds generated by high-throughput screening (HTS)
experiments. When possible, each compound was cross-linked to drugs annotated in DrugCentral, to separate approved drugs from the rest of the tested compounds. Matching
NCATS compounds to DrugCentral was conducted in three sequential steps: by InChI (International Chemical Identifier) [36], by synonym (name), and by matching CAS (Chemical
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Abstracts Service) Registry Numbers. First, NCATS molecules were matched by InChI.
Molecules that did not match were then queried by drug name and associated synonyms, as
annotated in DrugCentral. Finally, if not matched by either InChI or name, molecules were
matched by CAS number. If none of the above steps resulted in a match, then the molecule
in question was not classified as an approved drug. At the end of this process, 4,954 unique
molecules (2,273 approved drugs and 2,681 chemicals) were stored. Whenever possible, for
approved drugs and other chemicals, SMILES were retrieved from DrugCentral and from
PubChem, respectively. Otherwise, the original SMILES strings were retained. Bioactivity
data was mined according to the “curve class” and “maximum response” parameters [37].
The “curve class” evaluates the quality of the dose-response curve and, consequently, the
quality of the measurement. The “maximum response” is the maximum response value detected during the experiment. The “ACTIVITY CLASS” and a “SIGNIFICANCE CLASS”
were defined using criteria described in Table 4 and Table 5, respectively. As a final data
wrangling step, all compounds were categorized, and assay data grouped to have a unique
record per molecule for each assay. When more than one assay was measured for the same
molecule, only the datapoint with the best curve class was retained.
Table 2.3: Criteria applied to each experimental dataset that define the various activity
categories. Depending on the assay type, MAX RESPONSE could have either negative or
positive values. In any case, since a greater (absolute) value always
Cutoff

ACTIVITY CLASS

MAX RESPONSE 66

HIGH

33 ≥ MAX RESPONSE ≤ 66 MODERATE
MAX RESPONSE 33

2.4.1.2

LOW

Data Filtering

For each assay, the data was labeled as positive and negative. The compounds with “LOW”
activity class were treated as negative, whereas “HIGH” and “MODERATE” were treated
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Table 2.4: The significance classes represent the quality of the measurement and are defined
in accordance with the different shape of the dose-response curve (CURVE CLASS2) [37].
(a) A type 4 curve is a flat curve, which indicates that the compound does not show any
activity
CURVE CLASS2 SIGNIFICANCE CLASS
1.1 1.2 2.1 2.2

HIGH

1.3 1.4 2.3 3.4

MODERATE

3

LOW

4

INACTIVEa

5

INCONCLUSIVE

as positive compounds. Molecular structures were standardized using five different filters
using RDKit [38] features: (i) SMILES strings were converted into canonical SMILES
strings. Some of the SMILES were not converted SMILES, were discarded. (ii) RDKit Salt
Stripper was implemented to obtain the salt stripped molecules. The “donotRemoveEverything” feature helps by leaving the last salt when the entire canonical SMILES string
contains only the salts, (iii) The RDKit “Uncharger” feature neutralizes the molecules by
adding or removing hydrogen atoms, (iv) The canonical tautomer was used obtained from
RDKit, and (v) logP and logS filters were defined as follows: (logP < 1 and logP > 9)
and (logS > –3 and logS < -7.5). Such thresholds were arbitrarily defined to maximize the
number of negative data excluded while minimizing the positive data excluded. However,
for the 3CL dataset, logP and logS filters were not implemented. The final task was the
removal of duplicate compounds resulting from desalting, neutralizing, and standardizing
tautomers.
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2.4.1.3

Molecular Descriptors

A total of 22 features of three distinct types (fingerprints-based, pharmacophore-based,
and physicochemical descriptors based) were implemented. Fingerprints were converted
into a bit vector of either 1,024 or 16,384 lengths. Pharmacophore type was also a bit
vector of size 2,692, whereas RDKit and VolSurf+ descriptors were of length 200 and 128,
respectively.
Fingerprints-based: This includes the circular, path-based, and substructure keys [39,
40]. Circular fingerprints include the extended-connectivity fingerprints (ECFPx) and
feature-connectivity fingerprints (FCFPx), where x is 0, 2, 4, and 6 are the bond length
or diameter for each circular atom environment. ECFP consists of the element, number
of heavy atoms, isotope, number of hydrogen atoms, and ring information, whereas FCFP
consists of pharmacophore features. Substructure keys Avalon and the public Molecular
ACCess System (MACCS) are two distinct types of fingerprints that are substructure keys.
The Avalon fingerprint, used here, is a bit vector of size 1,024. It includes feature classes
such as atom count, atom symbol path, augmented atom, and augmented symbol path, etc.
MACCS structural keys are 166-bit structural key descriptors. Each bit here is associated
with a SMARTS pattern and belongs to the dictionary-based fingerprint class. Path-based
fingerprints include RDKx (where x is 5, 6, 7), topological torsion (TT), HashTT, atom
pair (AP), and HashAP. The size of each fingerprint is 1024 for all of them.
A longer version of the fingerprint, of 16384 bits, was also used for comparison. This
longer version is represented by the prefix “L”: LAvalon, LECFP6, LECFP4, LFCFP6 and
LFCFP4.
Pharmacophore-based:

Topological pharmacophore atomic triplets fingerprints

(TPATF) were obtained using maychemtools [41]. TPATF describes the ligand sites that
are necessary for molecular recognition of a macromolecule or a ligand, and passes that
information to the ML model to be trained. Ligand SMILES strings were passed through a
Perl script to generate TPATF. The basis sets of atomic triplets were generated using two
different constraints (i) triangle rule, i.e., the length of each side of a triangle cannot exceed
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the sum of the lengths of the other two sides; and (ii) elimination of redundant pharmacophores related by symmetry. The default pharmacophore atomic types Hydrogen Bond
Donor (HBD), hydrogen bond acceptor (HBA), positively ionizable (PI), negatively ionizable (NI), H (hydrophobic), and Ar (aromatic) were used during generation of TPAT [42].
Physicochemical descriptors: This includes the RDKit molecular descriptors and VolSurf+ descriptors. For RDKit descriptors, a set of 200 descriptors were used, which were
obtained from RDKit [38]. They are either experimental properties or theoretical descriptors, which are e.g. molar refractivity, logP, heavy atom counts, bond counts, molecular
weight, topological polar surface area. A total of 128 descriptors were obtained using VolSurf+ software. VolSurf+ is a computational approach aimed at describing the structural,
physicochemical and pharmacokinetic features of a molecule starting from a 3D map of
the interaction energies between the molecule and chemical probes (GRID-based molecular
interaction fields, or MIFs) [43]. VolSurf+ compresses the information present in MIFs into
numerical descriptors, which are simple to use and interpret [16].

2.5

Model Development

For each classifier, several machine learning models were developed, employing three categories of features and 22 distinct machine learning algorithms from the scikit-learn package.
Figure 2.8 briefly shows the workflow of the model generation. The three different categories of features employed were 1) chemical fingerprints, 2) physicochemical descriptors,
and 3) topological pharmacophore descriptors. For fingerprint-based descriptors, 19 different RDKit fingerprints were tested. For physicochemical descriptors, Volsurf+ and RDKit
descriptors were employed. For Topological pharmacophore descriptors, TPATF fingerprints from Mayachemtools were employed. For each model, input data was split into a
70% training set, 15% validation set, and 15% test set using a stratified sampling. Table 2.5
depicts the number of compounds used in training, validation, and test sets for each model.
Compounds discussed in the External Predictivity section (Figure 2.7) were not part of
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Figure 2.8: ML model development workflow
this workflow and are not included in Table 2.5. All of the models were trained leveraging
22 different classifiers available in scikit-learn. Initially, 968 different models were trained
using 22 classifiers (Complement Naive Bayes, Extreme Gradient Boosting, KNeighbors,
Gradient Boosting, Perceptron, One Vs Rest , Extra-Tree, Ridge, One Vs One, Bagging,
Random Forest, Output Code, Passive Aggressive, Linear SVC, Stochastic Gradient Descent, Logistic Regression, Extra Trees, Multinomial Naive Bayes, Ada Boost, Decision
Tree, Nearest Centroid, Multi-layer perceptron) and 22 distinct features (ECFP0, ECFP2,
ECFP4, LECFP4, ECFP6, LECFP6, FCFP2, FCFP4, LFCFP4, FCFP6, LFCFP6, RDK5,
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RDK6, RDK7, Avalon, LAvalon, MACCS, HashTT, HashAP, VolSurf+, TPATF, and RDKit descriptors) based on the default configurations of the classifiers. Finally, the best
suited combination of classifiers and features were selected for hyperparameter tuning.
Table 2.5: Summary of datasets used for each model
Total
Type

Train Valid

Test

Train

Valid

Test

Count
Actives count count count Actives Actives Actives

CPE

736

368

532

102

102

266

51

51

cytotox

1662

877

1163

249

250

581

125

125

AlphaLisa 1260

630

882

189

189

441

94

95

TruHit

1658

829

1161

248

249

580

124

125

ACE2

206

103

144

31

31

72

15

16

3CL

442

221

309

66

67

154

33

34

2.5.1

Similarity Search

We used an ECFP4 bit vector fingerprint with 1024 bits, and TC calculations, for the
fingerprints present in the database along with that of a query molecule, are computed on
the fly. The Tanimoto coefficient represents the overlap of features between molecules as the
ratio of the number of common features to the total number of features in each fingerprint.
The coefficient ranges from 0 to 1, with 1 corresponding to identical fingerprints.

2.5.2

Hyperparameter Optimization

The best performing default models based on validation sets were selected for hyperparameter optimization. These models were optimized using a grid search method. Scikit-learn
provides the package for grid search hyperparameter optimization using cross validation.
However, it is slow and does not offer a grid search with a separate validation set. Thus, we
used a freely available software “hypopt” for the hyperparameter tuning of each model [44].
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The models were optimized and selected based on the validation F1 score. The outperforming models were saved and used for the evaluation of external datasets.

2.5.3

Evaluation Metrics

The model performances were evaluated by five distinct evaluation metrics available in
scikit-learn: accuracy, recall, precision, F1 score, and area under the receiver operating
characteristic (ROC) curve (AUC). In general, the accuracy measures the total number of
correct predictions among the total numbers of instances evaluated. The recall was used
to measure the fraction of total positives that are correctly classified, whereas precision
estimates the fraction of total positives that are correctly predicted from the total predicted
positives. F1 score is the harmonic mean of recall and precision. The score ranges from 0
to 1 for each of the metrics, where 1 is a perfect score. Moreover, AUC was computed for
each of the classifiers. A perfect classifier yields an AUC of 1, whereas a random model has
an expected AUC of 0.5.

2.6

Implementation and Accessibility

2.6.0.1

Web Portal

REDIAL-2020 is available online at http://drugcentral.org/Redial.

2.6.1
All

Code Availability
of

the

codes

and

the

trained

https://github.com/sirimullalab/redial-2020.
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models

are

available

at
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Xavier de Lamballerie, and Bruno Coutard. In vitro screening of a FDA approved
chemical library reveals potential inhibitors of SARS-CoV-2 replication.
[28] Laura Riva, Shuofeng Yuan, Xin Yin, Laura Martin-Sancho, Naoko Matsunaga, Sebastian Burgstaller-Muehlbacher, Lars Pache, Paul P. De Jesus, Mitchell V. Hull, Max
Chang, Jasper Fuk-Woo Chan, Jianli Cao, Vincent Kwok-Man Poon, Kristina Herbert, Tu-Trinh Nguyen, Yuan Pu, Courtney Nguyen, Andrey Rubanov, Luis MartinezSobrido, Wen-Chun Liu, Lisa Miorin, Kris M. White, Jeffrey R. Johnson, Christopher
Benner, Ren Sun, Peter G. Schultz, Andrew Su, Adolfo Garcia-Sastre, Arnab K. Chatterjee, Kwok-Yung Yuen, and Sumit K. Chanda. A large-scale drug repositioning
survey for sars-cov-2 antivirals. bioRxiv, 2020.
[29] Jing Xing, Rama Shankar, Aleksandra Drelich, Shreya Paithankar, Eugene Chekalin,
Thomas Dexheimer, Surender Rajasekaran, Chien-Te Kent Tseng, and Bin Chen.
Reversal of infected host gene expression identifies repurposed drug candidates for
COVID-19. bioRxiv, April 2020.
[30] Ka-Tim Choy, Alvina Yin-Lam Wong, Prathanporn Kaewpreedee, Sin Fun Sia, Dongdong Chen, Kenrie Pui Yan Hui, Daniel Ka Wing Chu, Michael Chi Wai Chan, Peter Pak-Hang Cheung, Xuhui Huang, Malik Peiris, and Hui-Ling Yen. Remdesivir,
lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Antiviral Res., 178:104786, June 2020.
[31] Carmen Mirabelli, Jesse W Wotring, Charles J Zhang, Sean M McCarty, Reid
Fursmidt, Tristan Frum, Namrata S Kadambi, Anya T Amin, Teresa R O’Meara,
Carla D Pretto, Jason R Spence, Jessie Huang, Konstantinos D Alysandratos, Darrell N Kotton, Samuel K Handelman, Christiane E Wobus, Kevin J Weatherwax,
George A Mashour, Matthew J O’Meara, and Jonathan Z Sexton. Morphological cell

54

profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID19. bioRxiv, June 2020.
[32] Laura Riva, Shuofeng Yuan, Xin Yin, Laura Martin-Sancho, Naoko Matsunaga, Lars
Pache, Sebastian Burgstaller-Muehlbacher, Paul D De Jesus, Peter Teriete, Mitchell V
Hull, Max W Chang, Jasper Fuk-Woo Chan, Jianli Cao, Vincent Kwok-Man Poon,
Kristina M Herbert, Kuoyuan Cheng, Tu-Trinh H Nguyen, Andrey Rubanov, Yuan
Pu, Courtney Nguyen, Angela Choi, Raveen Rathnasinghe, Michael Schotsaert, Lisa
Miorin, Marion Dejosez, Thomas P Zwaka, Ko-Yung Sit, Luis Martinez-Sobrido, WenChun Liu, Kris M White, Mackenzie E Chapman, Emma K Lendy, Richard J Glynne,
Randy Albrecht, Eytan Ruppin, Andrew D Mesecar, Jeffrey R Johnson, Christopher
Benner, Ren Sun, Peter G Schultz, Andrew I Su, Adolfo Garcı́a-Sastre, Arnab K Chatterjee, Kwok-Yung Yuen, and Sumit K Chanda. Discovery of SARS-CoV-2 antiviral
drugs through large-scale compound repurposing. Nature, 586(7827):113–119, October
2020.
[33] Jeff Janes, Megan E Young, Emily Chen, Nicole H Rogers, Sebastian BurgstallerMuehlbacher, Laura D Hughes, Melissa S Love, Mitchell V Hull, Kelli L Kuhen, Ashley K Woods, Sean B Joseph, H Michael Petrassi, Case W McNamara, Matthew S
Tremblay, Andrew I Su, Peter G Schultz, and Arnab K Chatterjee. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment
of cryptosporidiosis. Proc. Natl. Acad. Sci. U. S. A., 115(42):10750–10755, October
2018.
[34] Jonathan H Shrimp, Stephen C Kales, Philip E Sanderson, Anton Simeonov, Min
Shen, and Matthew D Hall. An enzymatic TMPRSS2 assay for assessment of clinical
candidates and discovery of inhibitors as potential treatment of COVID-19. ACS
Pharmacol Transl Sci, 3(5):997–1007, October 2020.
[35] Michael R Berthold, Nicolas Cebron, Fabian Dill, Thomas R Gabriel, Tobias Kötter,

55

Thorsten Meinl, Peter Ohl, Christoph Sieb, Kilian Thiel, and Bernd Wiswedel. KNIME: The konstanz information miner, 2008.
[36] Stephen R Heller, Alan McNaught, Igor Pletnev, Stephen Stein, and Dmitrii
Tchekhovskoi. InChI, the IUPAC international chemical identifier. J. Cheminform.,
7:23, May 2015.
[37] Ramakrishna Seethala and Litao Zhang. Handbook of Drug Screening. CRC Press,
April 2016.
[38] Greg Landrum and Others. RDKit: Open-source cheminformatics. 2006.
[39] Sereina Riniker and Gregory A Landrum. Open-source platform to benchmark fingerprints for ligand-based virtual screening. J. Cheminform., 5(1):26, May 2013.
[40] David Rogers and Mathew Hahn. Extended-connectivity fingerprints. J. Chem. Inf.
Model., 50(5):742–754, May 2010.
[41] Manish Sud. MayaChemTools: An open source package for computational drug discovery. J. Chem. Inf. Model., 56(12):2292–2297, December 2016.
[42] Fanny Bonachera, Benjamin Parent, Frederique Barbosa, Nicolas Froloff, and Dragos Horvath. Fuzzy tricentric pharmacophore fingerprints. part 1. topological fuzzy
pharmacophore triplets and adapted molecular similarity scoring schemes, 2007.
[43] P J Goodford. A computational procedure for determining energetically favorable
binding sites on biologically important macromolecules. J. Med. Chem., 28(7):849–
857, July 1985.
[44] Hypopt. https://github.com/cgnorthcutt/hypopt.

56

2.7

Appendix

Figure 2.9: PCA loadings plot of the compounds tested in NCATS SARS-CoV-2 experiments based on VolSurf+ descriptors. logP/logD descriptors are highlighted in green. logS
descriptors are highlighted in orange.

57

Figure 2.10: PCA scores plot of the compounds tested in NCATS 3CL inhibition assay
based on VolSurf+ descriptors. HIGH/MODERATE activity compounds are highlighted
in black. LOW activity compounds are highlighted in orange.
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Figure 2.11: Comparison of CPE models based on features (a, b) and 22 different classifiers
(c, d)

Figure 2.12: Comparison of cytotox models based on features (a, b) and 22 different classifiers (c, d)
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Figure 2.13: Comparison of AlphaLISA models based on features (a, b) and 22 different
classifiers (c, d)

Figure 2.14: Comparison of TruHit models based on features (a, b) and 22 different classifiers (c, d)
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Figure 2.15: Comparison of ACE2 models based on features (a, b) and 22 different classifiers
(c, d)

Figure 2.16: Comparison of 3CL models based on features (a, b) and 22 different classifiers
(c, d)

61

Figure 2.17: Validation/test scores obtained for different CPE models

Figure 2.18: Validation/test scores obtained for different cytotox models

Figure 2.19: Validation/test scores obtained for different AlphaLISA models
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Figure 2.20: Validation/test scores obtained for different TruHit models

Figure 2.21: Validation/test scores obtained for different ACE2 models

Figure 2.22: Validation/test scores obtained for different 3CL models
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Chapter 3
Prediction of Ligand Activity at
Subcellular Location
This chapter is adopted from: Srijan Verma, Govinda KC, Mahmudulla Hassan, suman
sirimulla, Tudor I. Oprea. “Prediction of Ligand Activity at Subcellular Location”. (not
submitted yet).
Abstract Understanding how xenobiotics are distributed across subcellular location can
play a crucial role in assessing drug efficacy and toxicity. Such knowledge would widen
therapeutic windows by allowing specific receptors to be targeted efficiently. Extensive
in–silico research has provided a wealth of information on protein subcellular localization
(micro-compartmentation), and how this corresponds to protein function. However, analogous research on drug and drug-like micro-compartmentation is limited. Based on datasets
that provide information on the subcellular locations of proteins and their ligands, we developed machine learning models for 40 subcellular locations. Machine learning models
were trained and validated based on the grid search method and best models based on
Cohen’s Kappa scores were selected.
Availability:

GitHub:

https://github.com/sirimullalab/subcellular prediction,

Docker: sirimullalab/subcellularlocation
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3.1

Introduction

Human cells are internally organized into many organelles (subcellular compartments).
Over a cell’s life cycle, its constituents are continually renewed and localized to their proper
locations in the cell [15]. Subcellular activities enabled by micro-compartmentation (such
as absorption, distribution, metabolism, and elimination) are pertinent to drug targeting.
In fact these activities determine a drug’s pharmacological effects and explain how different
tissues and organs can be exposed to drugs at different levels [23]. Nevertheless, implementing subcellular drug targeting, at the level of organelle, is often challenging despite
the wide range of drug treatments available.
Often, a drug must localize to a specific subcellular region to be effective. For example, paclitaxel acts on microtubules and some drugs need to be accumulated in lysosome,
mitochondria and endoplasmic reticulum (ER) [12]. In general, the benefits of highly
specific targeting include lowering the dose of drug required for the desired effect, minimizing side effects and slowing down the progress of multi-drug resistance such as in cancer
chemotherapy [19]. Moreover, failure to understand how cells traffic their constituents
often leads to increased toxicity and therapeutic failure [15], such as in drug-resistant cancer [20]. Consequently, precise subcellular drug delivery holds great promise in improving
chemotherapy [20].
In the literature, there are some in–silico studies on protein subcellular localization
that aim to understand protein function and reveal the mechanism of molecular interactions [6, 7, 9]. However, in silico models to predict small molecule subcellular localization
are not fully explored. For example, Yang et al. [22] developed a statistics-based multiclassification model to predict chemical subcellular localization using six different machine
learning algorithms. This was limited to four subcellular regions (lysosome, mitochondria,
nucleus, and plasma membrane). Herein we report the first in silico study for predicting
drug localization for 40 different subcellular regions. We manually curated the subcellular locations and collected ligand data from the PDSP Ki [18] and Pharos databases [13].
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Forty different classification models (one for each subcellular location) were developed by
exploring various RDKit features[5] and trained using different machine learning (ML) classifiers from Scikit-learn [14]. We extensively evaluated the performance of different features
and ML algorithms and discussed the results. Models were tested across five evaluation
metrics, and the best models, after performing grid search, were implemented. To better
understand the chemical diversity within our dataset and the applicability of our models,
we conducted a simple scaffold analysis on molecules whose results are explained in the
following sections.

3.2

Methods

3.2.1

Datasets

Data was collected from various sources. Labelled data (i.e. UniProt IDs mapped with
their subcellular locations) was manually curated and ligand data was collected from PDSP
Ki [18] and Pharos databases [13]. PDSP Ki database was downloaded from their website
in a csv format. It contained ligand SMILES patterns, their Ki values, and gene IDs. A
mapping of these Gene IDs with their UniProts was obtained from Pharos. Additional
ligand data was collected from Pharos mySQL db (version - 5.4.4), which incorporates
SMILES patterns mapped with their UniProt IDs. SQL was used for collecting data from
Pharos using the data mining platform, Knime [8].
Pharos mySQL database had a total of 61 tables, out of which two tables contained
a SMILES column (with table names: cmpd activity and drug activity). UniProt IDs
were present in the protein table. The UniProt column in the protein table matches the
target id column in the cmpd activity and drug activity tables. Intersection of protein
table along with cmpd activity and drug activity tables was taken first. This data was
merged after that, and 2,210 UniProt IDs mapped to many ligands was obtained. UniProt
IDs having no ligand data were removed. Labelled data, which was manually curated, had
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17,864 UniProts mapped to different subcellular locations. Out of these, 2,210 belonged to
either Tchem or Tclin [3]. These are the proteins for which the interaction with drugs is
annotated in the literature. Intersection of this labelled data (i.e UniProts mapped with
their subcellular locations) was taken with PDSP and Pharos, and 2,167 UniProts, their
subcellular locations, each mapped to various SMILES patterns was obtained.

3.2.2

Data curation

PDSP and Pharos datasets were filtered separately, after which they were merged. All the
ligands for Pharos and PDSP were first converted to canonical SMILES and were then
filtered using certain thresholds as shown in Tables 3.1.
Table 3.1: Thresholds used for Pharos and PDSP data

Family name

Pharos

PDSP

(Threshold used) (Threshod used)
Kinase

≤30nM

≤30nM

GPCRs

≤100nM

≤100nM

Nuclear Receptors

≤100nM

≤100nM

Ion Channels

≤ 10μM

≤ 10μM

Non-IDG Family

≤ 10μM

≤ 10μM

Pharos: Since only the ligands which follow the aforementioned criteria were stored in
Pharos, no filtering was required. Hence, the ligand data was used as it was retrieved.
Ligands for 2,167 UniProt IDs were present in Pharos, and all of them belonged to either
Tchem or Tclin. Each UniProt ID was mapped with many ligands. Protein families for
each of the UniProt IDs were either manually curated or obtained from Pharos ‘protein’
table. UniProt IDs were labelled with their corresponding subcellular locations by taking
an inner join of this data along with the labelled dataset. First, the pre-processing step was
to convert all the subcellular locations (output target) to lowercase. Next, actin filament
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was replaced with actin filaments for consistency (Knime node String Manipulation, was
used here).
Each of the subcellular locations was split by ‘—’ and the number of rows increased
accordingly (Knime node - python script 1-1).
PDSP Ki: This database contained gene IDs mapped with their ligands. Since we were
only focusing on humans, we retained PDSP data only where species were in {‘HUMAN’, ‘?
HUMAN’, ‘HUMAN M3’, ‘HUMAN M4’}. UniProt IDs, protein family, and the subcellular
locations for each of the gene IDs present here were obtained from the manually curated
database. Ligands for which no subcellular location was found were removed. Output
target (subcellular location) was filtered in a similar manner as for the Pharos database.
Finally, Pharos and PDSP Ki databases were merged and ligand data for 44 different
subcellular locations was obtained. Four out of these 44 subcellular locations had data for
less than 10 ligands, thus they were dropped.
Consequently, we developed individual models for each of the subcellular locations by
treating each of the models as a binary class classification problem. Accordingly, we generated 40 csv files by labeling the desired subcellular location as +ve, and the rest as -ve.
Duplicate SMILES were present in the +ve and -ve portions for a subcellular location. To
solve this problem, we removed those duplicates from +ve parts and -ve parts (retaining
just the first duplicate). Subsequently, no SMILES in the -ve data should be present in the
+ve data (achieved via the python pandas module). We concatenated these sets (+ve and
-ve) and repeated for all 40 subcellular locations. Table 3.2 shows a summary of the full
dataset.

3.2.3

Descriptors

A total of 21 features of five different kinds (Circular, Path-based, Substructure keys
[16, 17], RDKit descriptors, and VolSurf+ [10]) were generated for each of the 40 subcellular locations. Fingerprints were converted to a bit-vector of either 1024 or 16,384
length, whereas RDKit and VolSurf+ descriptors had 200 and 128 different features re68

spectively.
Circular fingerprints: These include the extended-connectivity fingerprints (ECFPx)
and feature-connectivity fingerprints (FCFPx), where x is 0, 2, 4, and 6 are the bond length
or diameter for each circular atom environment. ECFP consists of the element, number of
heavy atoms, isotope, number of hydrogens, and ring information; whereas FCFP consists
of pharmacophore features.
Substructure keys: Avalon and the public Molecular ACCess System (MACCS) are two
different types of fingerprints that are substructure keys. The Avalon fingerprint, used here,
is a bit vector of size 1,024. It includes feature classes such as atom count, atom symbol
path, augmented atom, augmented symbol path, and so on. MACCS structural keys are
166-bit structural key descriptors. Each bit here is associated with a SMART pattern and
belongs to the dictionary-based fingerprint class.
Path-based fingerprints: This includes RDKx (where x is 5, 6, 7), topological torsion
(TT), HashTT, atom pair (AP), and HashAP. The size of fingerprints is 1024 for all of
them.
Long fingerprints: A longer version of fingerprint, of 16384 bits, was also used for comparison. This longer version is represented by the prefix “L”: LAvalon, LECFP6, LECFP4,
LFCFP6 and LFCFP4.
RDKit descriptors: A set of 200 descriptors were used which were obtained from RDKit.
They are either experimental properties or theoretical descriptors, which are molar refractivity, logP, heavy atom counts, bond counts, molecular weight, topological polar surface
area, to name few.
VolSurf+ descriptors: A total of 128 descriptors were obtained using VolSurf+ software.
VolSurf+ is a computational approach aimed to describe the structural, physicochemical
and pharmacokinetic features of a molecule starting from a 3D map of the interaction energies between the molecule and chemical probes (GRID-based Molecular Interaction Fields,
or MIFs [11]). VolSurf+ compresses the information present in MIFs into numerical descriptors, which are simple to understand and to interpret [10].
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HScaf Scaffolds: HScaf [4] is an open source library for chemical scaffold analysis, which
implements the HierS hierarchical scaffolds algorithm [21]. All the possible scaffolds over
the entire dataset were computed and a total of 184,022 unique scaffolds were found.

3.2.4

Performance Evaluation

To ensure the obtained ML model has good generalization ability for a new chemical entity,
an independent test was applied for this purpose. The model performance were evaluated
using various metrics: Accuracy, F1 score, Precision, Recall, Cohen’s Kappa, and AUC
(See Chapter 1 for more details about the evaluation metrics).
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3.3
3.3.1

Results and Discussions
Models development

Figure 3.1: The workflow

For each model the starting data set was split into training (70%), validation (15%), and
test set (15%). The ligands in our dataset belonged to 12 different protein families (Kinases, Non-IDG Family Targets, Enzyme, Ion Channels, GPCRs, Transporter, Nuclear
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Receptors, Epigenetic, TF, TF; Epigenetic, Signaling Molecule, and Other). We used a
stratified approach in splitting the data. The data was split based on output column and
protein family. For example the data coming from GPCR family or any other protein
family described are distributed 70% in training, 15% in validation and 15% in test sets
to ensure the diversity of different proteins are distributed among all three data sets. In
splitting and stratifying the data, we combined the protein families having the smallest
and second smallest number of ligands. That is, if the number of ligands lying in a protein family was low and it could not be stratified, then we merged that family with the
second lowest family number. This process was repeated until stratification and splitting
of the data was achieved. In order to optimize the performance of a model in prediction,
its algorithm hyperparameters can be tuned with a procedure called grid search. Thus,
the first 15% split of the data (validation set) set was used to provide an evaluation of the
model predictivity improvement during hyperparameter tuning. The second 15% split of
the data (test set) was used for the final unbiased evaluation of the best model. All models
were trained leveraging 28 different classifiers available in scikit-learn. Initially, 23,520 different models were trained using 28 classifiers (Extra Tree, Ada Boost, MLP, Multinomial
NB, Logistic Regression, Random Forest, Ridge, Bagging, SGD, Linear SVC, Nearest Centroid, Perceptron, XGB, One Vs Rest, Passive Aggressive, Linear Discriminant Analysis,
Complement NB, Output Code, Hist Gradient Boosting, Decision Tree, Quadratic Discriminant Analysis, One Vs One, Gaussian NB, Gaussian Mixture, Bernoulli NB, Extra Trees,
Bayesian Gaussian Mixture, Dummy) and 21 different features (ECFP0, ECFP2, ECFP4,
LECFP4, ECFP6, LECFP6, FCFP2, FCFP4, LFCFP4, FCFP6, LFCFP6, RDK5, RDK6,
RDK7 Avalon, LAvalon, MACCS, HashTT, HashAP, VolSurf+, and RDKit descriptors)
based on the default configurations of the classifiers. Finally, the best suited combination
of classifiers and features were selected. Results for validation and test sets are dipcted in
3.2 and figure 3.3. Tables 3.3 and 3.4 show the evaluated scores of all of 40 subcellular
locations. The overall scores for different classifiers are shown in Figures 3.11, 3.12, 3.13,
3.14.
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3.3.1.1

Model development using scaffolds

HScaf program was used to compute all possible scaffolds over the entire dataset and more
than 180,000 scaffolds were found. Successively, distribution of scaffolds over different
subcellular locations with a focus on activity (positives vs negatives) and set (training,
validation and test) was performed. Based on the list of scaffolds (ids) and scaffolds hierarchy within the molecule, three different type of features, namely, all scaf, all scaf pca
and top scaf, were generated. (More information given in SI)
All scaf: All the scaffold ids present for each Smiles were first one-hot encoded (using
MultiLabelBinarizer [1] function). The one hot encoded vector for each ligand was then
converted into a sparse vector (in CSR format [2]) for memory optimization. Finally, a
sparse matrix of size 217,526×184,022 was obtained and was used as a dictionary to map
ligands for all 40 subcellular locations.
All scaf pca: The principle component analysis (PCA) algorithm was used, on the mentioned above sparse matrix, to reduce the dimensionality from 184,022 to 2,000 and a dense
matrix was used for model training.
Top scaf: These features were obtained considering only the top hierarchy scaffolds for
each ligand. A total of 81,564 unique top scaffolds were one hot encoded and converted to
a sparse matrix.
Ten different models (Random Forest, MLP, XGB, Bagging, Extra Trees, SGD, Logistic
Regression, Linear SVC, One Vs Rest, and Passive Agg.) were trained and evaluated for
the above described feature types.
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Figure 3.2: Plot showing the performance of 40 models on the validation set

Figure 3.3: Plot showing the performance of 40 models on the test set
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3.3.1.2

Comparison of different models

Performance of the models were evaluated based on Accuracy, F1–Score, Cohen’s Kappa
Score, and AUC. The evaluated scores of all metrics were > 0.72 for validation set and
> 0.67 for test set for all subcellular locations except for golgi membrane and intermediate
filaments. The average scores were Accuracy: 0.992, F1-Score: 0.887, Cohen’s Kappa:
0.882, AUC: 0.927 for validation set and 0.991, 0.887, 0.871, 0.92 respective scores for the
test set. Amongst the 28 classifiers, the ones which were found to work best for our dataset
were- MLP, Logistic Regression, RF, Bagging, SGD, One Vs Rest, Passive Aggressive, Extra
Trees. For 24 out of the 40 locations, MLP was found to work the best outperforming other
models.
3.3.1.3

Comparison of different features

Features which worked well were: ECFP6, LECFP4, ECFP4, FCFP6, RDK6, LFCFP6,
LECFP6, HashTT, FCFP4, LAvalon, LFCFP4, Avalon. Amongst all the features, LECFP6
was found to work well for most of the locations (19/40). Long fingerprints, having a bit
vector of 16,384 was observed to work better than the short ones, of bit vector 1,024. Two
different molecular descriptors, namely RDKit and VolSurf+ were also used for training
the models. Performance of models based on RDKit descriptors was found to be higher
than that of VolSurf+ descriptors, but less than that of long and short fingerprints.
In order to provide a scientific explanation on why fingerprint-based models were outperforming molecular-based models we analyzed the scaffold distribution across the subcellular
locations and by focusing on activity (positives vs negatives) differences and set (training,
validation and test) differences.
A first attempt by simply exploring the different molecule activity distribution across
each location gave no interesting hints for this purpose, but it confirmed that the preferred
locations for drug targets are either the cytosol or the cell membrane (see Figure 3.7). We
also cannot exclude the possibility that the other subcellular locations that are unexplored
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may be “home” of new interesting targets.
We then analyzed the scaffold distribution. Interestingly, both Figure 3.8 and Figure 3.9
reflect the activity distribution shown in Figure 3.7. Furthermore, the number of scaffolds
that are present in both positive and negative sets (depicted in orange on the plots) is
small. Thus, scaffolds present in positives are not likely to be present in negatives. We
believe this is the reason at the basis of fingerprint models high performances. In fact,
fingerprints are very sensible to scaffolds and they can easily detect them. However, this
might decrease the importance of machine learning because if it is so easy to detect positive
and negative scaffolds, then what is the reason for creating a model to do the job? Hence,
in the machine learning prospective, RDkit and VolSurf+ descriptions might be preferable
because such procedures are less sensible to scaffolds.
In order toverify the possible model bias in predicting only known scaffolds, we wanted to
know the amount of “positive scaffolds” that were specific of the training set and specific of
the remaining data. Hence, we explored their positives only distribution across the training
set and the other two sets (validation and test). In Figure 3.10, for each model, around
20% of scaffolds are present in the test set or in the validation set, but not in the training
set. This is an interesting finding because the models are forced to predict, in addition to
scaffolds that they know (i.e. those that are present also in the training set), also scaffolds
that they do not know. We did not explore what the situation is for negatives, but we
assume it is similar to positives.
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Figure 3.4: Plots showing the performance of models based on different features

Figure 3.5: Comparison of RDKit FPs, RDKit, VolSurf+ descriptors and HScaf Scaffolds
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Figure 3.6: Box plots showing different evaluated scores

Figure 3.7: Molecules vs Activities distribution plot. For each model (i.e. subcellular
location) positive molecules (+vs) are depicted in green and negative molecules (-ve) are
depicted in blue
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Figure 3.8: Scaffolds vs Activities distribution plot. For each molecule only the first scaffold
in the hierarchy is reported. Scaffolds present in positive molecules only are depicted in
green; scaffolds present in negative molecules only are depicted in blue; scaffolds present in
both positive and negative molecules are depicted in orange.

Figure 3.9: Scaffolds vs Activities distribution plot. For each molecule all scaffolds in the
hierarchy are reported. Scaffolds present in positive molecules only are depicted in green;
scaffolds present in negative molecules only are depicted in blue; scaffolds present in both
positive and negative molecules are depicted in orange.
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Figure 3.10: Training scaffolds vs rest (validation + test) scaffolds distribution plot. “positive only” scaffolds are reported. Scaffolds that are unique of the training set are depicted
in green; scaffolds that are unique of the other sets (validation and test) set are depicted
in orange; scaffolds that are present in all three sets are depicted in blue

3.3.1.4

Scaffold Analysis

The program HScaf [4], an in-house version of the scaffold hierarchy tree methodology
(implemented at University of New Mexico), was used to compute all possible scaffolds
over the entire dataset. More than 180,000 scaffolds were found. Successively, scaffolds
were matched to original structures and, consequently, to datasets (training, validation
and test) and activities (positive: +ve and negative: -ve).
Complementary to the scaffold distribution analysis, also the distribution of activities
across each location was performed and the results are shown in Figure 3.7. For each
dataset, the distribution of scaffolds in terms of activity (i.e. positive if the scaffold is
within an active molecule and negative if the scaffold is within an inactive molecule) was
performed and the results can be seen in Figure 3.8. If not considering only the top hierarchy
but all scaffolds within a molecule, the distribution shown in Figure 3.9 was obtained. The
“positive scaffolds” only distribution across datasets for the same model was obtained with
similar operations (see Figure 3.10).
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3.4

Conclusion

In summary, we have developed some reliable predictive models for localization for 40
different subcellular locations. Manually curated data on protein localization along with
data obtained from Pharos and PDSP Ki databases were used. Several features from RDkit
and different machine learning algorithms from scikit-learn were used in training the models.
The best models were selected based on model’s Cohen Kappa on its validation set. MLP
showed best results in most of cases. Among 21 different molecular features mainly based
on RDKit, LECFP6 outperformed others. However, a scaffold analysis revealed that very
few scaffolds are likely to be in positive and negative molecules simultaneously. This can
potentially bias fingerprint-based strategies. Hence, using other methodologies such as
VolSurf+ might be preferable, despite the lower performances in prediction.
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3.5

Appendix

Table 3.2: Summary of datasets
Subcellular Location

Active Inactive

actin filaments

5175

219874

cell junctions

6184

218865

centrosome

2464

222585

cytokinetic bridge

832

224217

cytoplasmic bodies

270

224779

cytoskeleton

3132

221917

cytosol

60633

164416

endoplasmic reticulum

6955

218094

endosomal membrane

75

224974

endosome

1770

223279

er lumen

4599

220450

er membrane

8637

216412

focal adhesions

5228

219821

golgi apparatus

16932

208117

golgi lumen

4222

220827

golgi membrane

582

224467

intermediate filaments

500

224549

lysosomal membrane

397

224652

lysosome

1539

223510

membrane protein

439

224610

microtubule organizing center 1600

223449

microtubules

2729

222320

midbody

1281

223768
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mitochondria

14383

210666

mitochondrial membrane

3096

221953

mitochondrial protein

2715

222334

mitotic spindle

927

224122

nuclear bodies

2203

222846

nuclear membrane

8427

216622

nuclear speckles

6355

218694

nucleoli

6612

218437

nucleoli (fibrillar center)

1753

223296

nucleoplasm

28154

196895

nucleus

29811

195238

peroxisome

810

224239

plasma membrane

131862

93187

rods and rings

485

224564

secreted

9670

215379

vesicle membrane

847

224202

vesicles

47212

177837

Table 3.3: Validation results for 40 models
Target

Feature Models

ACC κ

actin filaments

lecfp6

MLP

0.997

0.921 0.923 0.95

cell junctions

lecfp4

MLP

0.994

0.886 0.889 0.933

centrosome

lecfp4

Bagging

0.997

0.869 0.87

0.909

cytokinetic bridge

lecfp4

E. Trees

0.998

0.74

0.808

cytoplasmic bodies

all scaf

Bagging

1

0.806 1.0
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F1

0.74

AUC

0.865

cytoskeleton

lecfp6

SGD

0.998

0.909 0.91

cytosol

lecfp6

MLP

0.955

0.884 0.915 0.938

endoplasmic reticulum

ecfp4

MLP

0.989

0.811 0.816 0.881

endosomal membrane

rdk7

OneVsRest

1

1

1

endosome

lecfp6

P. Aggressive 0.998

0.84

0.841 0.895

er lumen

lecfp6

P. Aggressive 0.999

0.964 0.965 0.987

er membrane

lecfp6

MLP

0.996

0.941 0.943 0.963

focal adhesions

lfcfp6

MLP

0.997

0.94

golgi apparatus

lecfp4

E. Trees

0.981

0.856 0.866 0.903

golgi lumen

lecfp4

MLP

0.998

0.949 0.95

golgi membrane

lecfp4

MLP

0.999

0.788 0.788 0.885

intermediate filaments

laval

MLP

0.999

0.728 0.729 0.84

lysosomal membrane

lfcfp6

MLP

1

0.966 0.966 0.983

lysosome

lecfp6

MLP

0.999

0.91

membrane protein

lecfp4

P. Aggressive 1

0.938 0.938 0.962

microtubule organizing center ecfp6

MLP

0.999

0.897 0.897 0.939

microtubules

lecfp6

SGD

0.998

0.898 0.899 0.92

midbody

avalon

Bagging

0.997

0.756 0.757 0.856

mitochondria

lecfp4

MLP

0.988

0.893 0.899 0.933

mitochondrial membrane

lecfp4

MLP

0.999

0.957 0.957 0.973

mitochondrial protein

lfcfp6

E. Trees

0.998

0.915 0.916 0.931

mitotic spindle

lfcfp4

L. SVC

1

0.982 0.982 0.989

nuclear bodies

lecfp6

SGD

0.998

0.892 0.893 0.918

nuclear membrane

lecfp6

MLP

0.993

0.898 0.902 0.944

nuclear speckles

lfcfp6

MLP

0.987

0.74

nucleoli

lfcfp6

MLP

0.991

0.847 0.851 0.914
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0.92

1

0.941 0.966

0.971

0.911 0.952

0.747 0.843

nucleoli fibrillar center

fcfp6

MLP

0.998

0.863 0.864 0.91

nucleoplasm

lecfp4

MLP

0.97

0.86

nucleus

lecfp6

MLP

0.971

0.869 0.886 0.919

peroxisome

hashtt

MLP

0.999

0.913 0.914 0.959

plasma membrane

lecfp4

E. Trees

0.953

0.903 0.96

rods and rings

lfcfp6

L. SVC

1

0.993 0.993 0.993

secreted

avalon

MLP

0.989

0.869 0.875 0.932

vesicle membrane

ecfp6

MLP

0.999

0.845 0.845 0.897

vesicles

lecfp4

MLP

0.96

0.877 0.902 0.933

0.877 0.923

0.952

Table 3.4: Test results for 40 models
Target

Features

Models

actin filaments

lecfp6

MLP

0.997 0.925 0.927 0.952

cell junctions

lecfp4

MLP

0.994 0.881 0.884 0.933

centrosome

lecfp4

Bagging

0.997 0.857 0.858 0.913

cytokinetic bridge

lecfp4

E. Trees

0.998 0.748 0.749 0.816

cytoplasmic bodies

all scaf

Bagging

0.999

cytoskeleton

lecfp6

SGD

0.998 0.906 0.907 0.927

cytosol

lecfp6

MLP

0.954 0.882 0.913 0.938

endoplasmic reticulum

ecfp4

MLP

0.99

0.816 0.821 0.885

endosomal membrane

rdk7

OneVsRest

1

0.952 0.952 0.955

endosome

lecfp6

P. Aggressive 0.998 0.847 0.848 0.913

er lumen

lecfp6

P. Aggressive 0.998 0.961 0.962 0.977

er membrane

lecfp6

MLP

0.995 0.935 0.938 0.957

focal adhesions

lfcfp6

MLP

0.997 0.929 0.931 0.957

88

ACC

κ

0.76

F1

AUC

0.761 0.829

golgi apparatus

lecfp4

E. Trees

golgi lumen

lecfp4

MLP

0.998 0.956 0.957 0.975

golgi membrane

lecfp4

MLP

0.999 0.761 0.761

intermediate filaments

laval

MLP

0.999 0.671 0.672 0.806

lysosomal membrane

lfcfp6

MLP

lysosome

lecfp6

MLP

membrane protein

lecfp4

P. Aggressive

microtubule organizing center

ecfp6

MLP

0.998 0.885 0.886 0.929

microtubules

lecfp6

SGD

0.997 0.886 0.887 0.907

midbody

avalon

Bagging

0.997 0.732 0.733 0.835

mitochondria

lecfp4

MLP

0.987 0.885 0.892

mitochondrial membrane

lecfp4

MLP

0.998 0.941 0.942 0.972

mitochondrial protein

lfcfp6

E. Trees

0.998 0.886 0.888 0.908

mitotic spindle

lfcfp4

L. SVC

1

nuclear bodies

lecfp6

SGD

0.997

nuclear membrane

lecfp6

MLP

0.992 0.882 0.886

0.93

nuclear speckles

lfcfp6

MLP

0.987

0.85

nucleoli

lfcfp6

MLP

0.991 0.842 0.847 0.916

nucleoli fibrillar center

fcfp6

MLP

0.998 0.842 0.843 0.897

nucleoplasm

lecfp4

MLP

0.97

0.86

nucleus

lecfp6

MLP

0.97

0.866 0.883 0.918

peroxisome

hashtt

MLP

0.999 0.897 0.897

plasma membrane

lecfp4

E. Trees

0.95

0.898 0.957 0.949

rods and rings

lfcfp6

L. SVC

1

0.979 0.979 0.986

secreted

avalon

MLP

0.988 0.849 0.855 0.919

vesicle membrane

ecfp6

MLP

0.999 0.853 0.853
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0.98

1

0.847 0.857 0.894

0.96

0.96

0.88

0.992

0.999 0.922 0.923 0.952
1

0.936 0.937 0.947

0.93

0.974 0.975 0.982
0.86

0.75

0.861 0.899

0.756

0.878 0.926

0.93

0.89

vesicles

lecfp4

MLP

0.957

Figure 3.11: Plot showing the accuracy scores of different models

Figure 3.12: Plot showing the F1 scores of different models
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0.87

0.897 0.929

Figure 3.13: Plot showing the Cohen Kappa scores of different models

Figure 3.14: Plot showing the AUC scores of different models
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Chapter 4
KinasepKipred: A Predictive Model
for Estimating Ligand-Kinase
Inhibitor Constant (pKi)
This chapter is adopted from: Govinda KC, Mahmudulla Hassan, and suman sirimulla.
”KinasepKipred: A Predictive Model for Estimating Ligand-Kinase Inhibitor Constant
(pKi )”. (Submitted to Cell biology and Cell biophysics)

Abstract: Kinases are one of the most important classes of drug targets for therapeutic use. Algorithms that can accurately predict the drug-kinase inhibitor constant (pKi )
of kinases can considerably accelerate the drug discovery process. In this study, we have
developed computational models, leveraging machine learning techniques, to predict ligandkinase (pKi ) values. Kinase-ligand inhibitor constant (Ki ) data was retrieved from Drug
Target Commons (DTC) and Metz databases. Machine learning models were developed
based on structural and physicochemical features of the protein and, topological pharmacophore atomic triplets fingerprints of the ligands. Three machine learning models [random
forest (RFR), extreme gradient boosting (XGBoost) and artificial neural network (ANN)]
were tested for model development. The performance of our models were evaluated using
several metrics with 95% confidence interval. RFR model was finally selected based on
the evaluation metrics on test datasets and used for web implementation. The best and
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selected model achieved a Pearson correlation coefficient (R) of 0.887 (0.881, 0.893), rootmean-square error (RMSE) of 0.475 (0.465, 0.486), Concordance index (Con. Index) of
0.854 (0.851, 0.858), and an area under the curve of receiver operating characteristic curve
(ROC-AUC) of 0.957 (0.954, 0.960) during the internal 5-fold cross validation.
Availability: GitHub: https://github.com/sirimullalab/KinasepKipred, Implementation: https://drugdiscovery.utep.edu/pki/

4.1

Introduction

The interaction between drug and target facilitates the drug side effect prediction [26],
drug repurposing [22] and many others. Biochemical experiment methods for drug target
interactions are found highly costly and take a lot of time [33], whereas computational
methods are efficient, faster and more convenient [14]. Proteins are the good targets in
drug design [1] and get activated or inhibited by drug compounds. The binding of protein
with other ligand is found to be specific and it plays crucial role in many biological functions [16]. Protein kinase is an enzyme that plays a major role in the signal transduction
of cells by transferring a phosphate group from adenosine triphosphate (ATP) to other
proteins to their serine, threonine or tyrosine residues [35]. In this study, we are focused
on protein kinases because of their importance as drug targets for therapeutic use. They
play important roles in a wide range of diseases such as cardiovascular disorders, inflammatory diseases, gastrointestinal stromal tumors and cancer, and can serve as drug targets
for therapeutic use [10]. Kinase inhibitors that inhibit the activity of deregulated protein
kinases very efficacious in treating many diseases [12]. The US food and drug administration has approved 52 kinase inhibitors [28] and most of them are orally effective. The
interaction between the kinase and ligand is usually measured as binding affinity values in
terms of dissociation constant (Kd ), inhibition constant (Ki ) and half-maximal inhibitory
concentration (IC50 ). In this paper, we have used only the data corresponding to (Ki ) values for our dataset. Algorithms that predict drug-target associations [17, 34] and binding
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affinities were previously published by other researchers [13, 16, 25, 34, 36]. Yamanishi et
al. [34] proposed a supervised machine learning approach for categorizing drug-target pairs
as interacting or non-interacting based on an integrated model of chemical and genomic
molecular profile [34] as a binary class problem. Pahikkala et al. [25] introduced a method
KronRLS as a very first one to predict the non-binary drug target binding affinity values.
After that, Simboost [13], DeepDTA [36] and Indra et al. [16] are the most recent studies
based on machine learning models to predict the binding affinity scores. Simboost purposed
the gradient boosting machine learning model by using feature engineering to predict the
binding affinity values. It is the first non-linear method for continuous drug-target interaction prediction. DeepDTA is a deep learning based approach to predict drug-target binding
affinity using only sequences of proteins and drugs. They used convolution neural networks
(CNNs) to learn representations from the raw sequence data of proteins and drugs and
fully connected layers for the prediction. Simboost and DeepDTA are based on Davis [8],
Metz [21] and KIBA [13] data sets. Indra et al. [16] developed a Random forest ML based
on pdbbind database 2015. However, all aforementioned studies were generalized for all
types of proteins and were not kinase specific and also purposed models were not evaluated
by independent data sets. To our best knowledge, there are no algorithms that are specific
to kinase Ki predictions. In this study, the performance of three different machine learning
algorithms Random forest (RFR), Extreme gradient boosting (XGBoost), and Artificial
neural network (ANN) was developed and compared based on test dataset and external
dataset. The best model based on evaluated statistical metrics is selected and used for web
implementation.
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4.2

Methods

4.2.1

Datasets

Data was obtained from two different databases 1) Drug Target Commons (DTC) [31]and 2)
Metz [21]. DTC data contained 5,867,349 ligand-target pair associations. The dataset was
populated by the bioctivity types Ki (inhibition constant), Kd (dissociation constant), and
IC50 (half maximal inhibitory constant) for most of the ligand-target pairs. The “potent
targets” and “potent inhibitors” were defined based on cut-offs for the four most popular
bioactivity types (Kd , Ki , IC50 , and activity). Cutoffs of ≤ 100 nM (i.e., ≥ pKi of 7)
for the dose-response measurements (Kd , Ki , IC50 ) in biochemical assays, and ≤ 1000 nM
(i.e., ≥ pKi of 6) for the dose-response measurements (Kd , Ki , IC50 ) in cell-based and
other assay types [31] were used. The median of the bioactivity values was taken where
there were multiple bioactivity values. Since we were only focused on kinases with Ki , we
obtained only data pertinent to kinases with Ki values. We found 67,894 instances (ligandtarget pairs) from 5,983 compounds and 118 kinases. All Ki values were converted into
molar units and then recorded as the negative decadic logarithm as shown in equation (1).
The data set by Metz et al. [21] was also used as an external evaluation for the model.
It contained 150,000 instances of ligand-kinase Ki values composed of more than 3,800
compounds tested against 172 protein kinases. We filtered out this Metz data to create
a blind data set having 148 kinases with 240 compounds contributing 17,258 drug kinase
pairs which are distinct from the DTC dataset and were not used in our training and test
data. The summary of the datasets that we used for this work is shown in Table 4.1. Figure
4.1 shows the distribution of pKi values for (a) test dataset and (b) Metz dataset.


Ki
pKi = –log10
1e9
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(4.1)

Table 4.1: Summary of datasets
Data Sets Kinases Compounds Interactions
DTC

118

5983

67894

Metz

148

240

17258

Figure 4.1: Distribution of datasets (a) DTC data set (left) (b) Metz data set (right)

4.2.2

Molecular features

Protein sequences and SMILES patterns were used to generate the features of both DTC
and Metz datasets. Protein sequences were obtained from the Uniprot database providing
a file that contained UniProt IDs [7]. Similarly, compound SMILES strings were extracted
from ChEMBL based ChEMBL IDs provided in the datasets [11].
Protein features: Propy [5], a protein feature generator algorithm was used to generate
different features. The features that were used are as follows: i) Amino acid composition ii)
Dipeptide composition iii) Moreau -Broto autocorrelation iv) Moran autocorrelation (240)
v) Geary autocorrelation vi) composition transition distribution descriptors vii) Type I
pseudo amino acid composition descriptors (PACC) viii) amphiphilic (Type II) pseudo
amino acid composition descriptors ix) sequence order coupling number x) quasi sequence
order descriptors, and xi) conjoint triad features.
Ligand features: MayaChemTools [30], a cheminformatic toolkit, was used to generate
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ligand features. SMILES, which represent ligands, were passed through a Perl script [29]
to generate topological pharmacophore atomic triplets fingerprints (TPATFP) [3, 9, 15, 20,
32]. The descriptive values were obtained in csv files containing fingerprint vector strings
corresponding to molecular fingerprints. Pharmacophore atom types based on specified
values were assigned to all non-hydrogen atoms of each molecule and a distance matrix was
generated. A binned matrix was generated based on minimum distance, maximum distance
and bin size values. The minimum distance (Dmin ) and maximum distance (Dmax ) corresponds to the number of bonds between two atoms. Pharmacophore atom triplets basis
sets were generated for all unique atom triplets constituting atom pairs binned distance
between the minimum distance and maximum distance. Atom triplets basis set were generated based on the following constraints [20] (i) triangle rule, i.e., the length of each side of a
triangle cannot exceed the sum of the lengths of the other two sides; and (ii) elimination of
redundant pharmacophores related by symmetry. The possible values for pharmacophore
atom types are: Ar, CA, H, HBA, HBD, Hal, NI, PI, RA. However, we have used the
default values: HBD, HBA, PI, NI H, Ar. See Ref [3], where HBD= Hydrogen Bond
Donor, HBA=hydrogen bond acceptor, PI=positively Ionizable, NI=negatively ionizable,
Ar=aromatic, Hal=halogen, RA=ring atom, H=hydrophobic, and CA=chain atom. We
have used the default values for Dmin (= 1), Dmax (= 10) and Bsize (= 2) and the number of
distance bins Nbins (= 5). Thus, our atom triplet basis set was of size 2692.

4.2.3

Model development

Models were developed mainly based on the grid search method with 5-fold cross validation.
They were based on the Scikit-Learn machine learning (ML) library for Python [27]. We
used the 25% of data for the test set and 75% of the data for the training set. Three different
ML models (random forest, extreme gradient boosting, and artificial neural network) were
developed and we compared their performances using several evaluation metrics. The work
flow of model development is as shown in Figure ??. We also compared grid search vs
random search [2] for our random forest model to estimate the efficiency of each method.
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The three aforementioned ML algorithms are summarized as follws.

Figure 4.2: Project workflow

4.2.4

Random forest

Random forest [4] is an ensemble technique capable of performing both regression and
classification tasks. It uses multiple decision trees and trains each decision tree based on
technique called bootstrap aggregation. The prediction of test object is obtained by means
of voting [18]. We used three hyperparameters (n estimators, min samples split and max
features) to optimize the model. Our best model was obtained with the hyperparameter
combination of “n estimators”: 600, “min samples split”: 2, and “max features”: “auto”.
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4.2.5

Extreme gradient boosting

Extreme gradient boosting (XGBoost) [6] is an implementation of gradient boosted decision trees designed for speed and performance. It is a memory efficient and fast learning
algorithm through parallel and distributed computing. We tuned six hyperparameters: n
estimators, objective, colsample bytree, learning rate, max depth, and alpha to optimize
the model. Our best XGBoost model was developed with a combination of “n estimators”:
500, “objective”: “reg linear”, “colsample bytree”: 0.3, “learning rate”: 0.1, “max depth”:
5 and “alpha”: 10.

4.2.6

Artificial neural network

Artificial neural networks (ANNs) [19] are the brain-inspired systems which comprised of
artificial neurons, also known as nodes. An ANN usually consists of input layers, output
layers, and hidden layers most of the time. Input layers, also known as synapses are assigned
with weights which play play crucial role to select important signals for the output. The
weighted sum of each signal is applied to the activation function. Based on the activation
function, neuron will either pass on the signal or not. We used an input layer with 32 nodes,
and 4 hidden layers as 64, 128,128, 64, 32, and an output layer. As an activation function,
we used a rectified linear unit (ReLU) [23]. The final layer is activated by a linear function
to predict the output. Since the model was regression based, we used mean squared error
(MSE) as the ‘loss function’ and ‘adam’ as an optimizer. The learning was completed in
100 epochs with batch size 25.

4.3

Evaluation Metrics

Concordance index: Since the binding affinities in drug target interactions are continuous
values, one of the evaluation metrics used in this study was the concordance Index (Con.
Index) [24]. Con. Index measures the probability of two randomly drawn drug-target pairs
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with different label values are in the correct order. In other words, the prediction for the
larger affinity is larger than the prediction of the smaller affinity value. If di , dj , xi and xj
are the predicted and the actual affinity values in the case of larger and smaller binding
affinities respectively, Con. Index can be obtained as:
Con · Index =

1 X
h(di – dj )
Z x >x
i

(4.2)

j

where Z is the normalization constant, and h(u) is the step function. h(u) is 1.0, 0.5 and
0.0 for u > 0, u = 0 and u < 0 respectively. The Con. Index values lies in between 0.5 and
1.0. The value 0.5 corresponds to a random prediction, and as 1.0 for a perfect prediction.

Root mean square Error(RMSE): Define Ba and Bp as the actual and predicted
binding affinities. The error can be calculated as:
Error(Ei ) = Ba(i) – Bp(i)

(4.3)

MSE is calculated as the mean of the differences of the actual binding affinity values and
the calculated binding affinity values.
N

1X 2
Ei
MSE =
N

(4.4)

i=1

The RMSE is obtained as:

√
RMSE =

MSE

(4.5)

1X
Ba =
Ba(i)
N

(4.6)

Pearson’s correlation coefficient (R):
N

i=1
N

Bp =

1X
Bp(i)
N

(4.7)

i=1

PN
R = qP
N

i=1 (Ba(i)

i=1 (Ba(i)

– Ba )(Bp(i) – Bp )
P
2
– Ba )2 N
i=1 (Bp(i) – Bp )
100

(4.8)

Figure 4.3: Area under the ROC curve (a) Test dataset (left) (b) Metz dataset (right)
R measures the linear relationship between the actual and predicted binding affinity
scores. It lies in between -1 and 1.

Area under the curve (AUC): The area under the Receiver Operating Characteristic (ROC) curve is generally adopted in binary classification problems. However, it
can also be used to measure the regression problems by converting the quantitative values
into binary values by selecting thresholds. There are different ways to measure AUC for
regression problems. We have measured the average AUC converting the actual compound
kinase interaction values (i.e, Ki ) into binary labels given certain interaction thresholds.
The ROC curve was created by plotting the true positive rate (TPR) (i.e., sensitivity)
is plotted against the false positive rate (FPR) (i.e., 1 – specificity) for different cut-off
points. Accuracy is measured by the area under the ROC curve. An area of 1 (i.e, 100%)
represents a perfect test; an area of 0.5 (i.e, 50%) represents a random test. Figure 4.3
shows the plots of area under the ROC curve for (a) test dataset and (b) Metz dataset.
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4.4

Results and Discussions

The developed models were evaluated using several metrics such as root-mean-square-error
(RMSE), Pearson correlation coefficient (R), Spearman correlation coefficient (ρ), concordance index (Con. Index), and area under the receiver operating characteristic curve
(ROC-AUC). Tables 4.2, 4.3 and 4.4 show the scores obtained for the test and Metz dataset
(external test dataset) using three models. Among three different models, random forest
was found performing best with R 0.887, ρ 0.846, RMSE 0.475, Con. Index 0.854, and
AUC 0.957 for the test data set and 0.769, 0.669, 0.503, 0.749, and 0.938 respective scores
for the external dataset.

4.4.1

Performance of different ML algorithms on the test dataset

Out of 67894 instances, 75% of the data was used for training with 5-fold cross validation and 25% of the data were used as a blind test set. The results obtained for the test
set, for RFR, were R 0.887 (0.881, 0.893), ρ 0.846 (0.840, 0.853) RMSE 0.475 (0.465,
0.486), Con. Index 0.854(0.851, 0.858), and AUC 0.957 (0.954, 0.960); for XGBoost
were R 0.862(0.855,0.868), ρ 0.795(0.788,0.802), RMSE 0.522(0.512,0.533), Con. Index
0.805(0.801,0.810), and AUC 0.946(0.943,0.950); and for ANN were R 0.798 (0.794, 0.803),
ρ 0.716(0.710,0.722) RMSE 0.631(0.623,0.639), Con. Index 0.779 (0.774, 0.784), and AUC
0.933(0.926,0.940). All the metrics were computed with a 95% confidence interval. AUC
is generally used for classification problems. Since this was a regression problem, quantitative values were converted into binary values using certain thresholds. We used 10 different
equally spaced thresholds lying between 6 and 8 (based on DTC [31]) and the average AUC
was calculated.
After comparing the results for all the three models, we found that RFR outperformed
XGBoost and ANN. XGBoost had slightly lower performance than RFR, but it was better
than ANN. ANN did not work well with our dataset. The comparison of evaluated scores
on test dataset for three different models is shown in Figure 4.4(a). Figure 4.4(b) shows
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Figure 4.4: Test dataset Results (a) Comparison of performance of models (left)(b) Predictions from Random forest against actual values (right)
the predictions of RFR against actual values on test dataset.

4.4.2

Performance of different ML algorithms on an external
dataset

All the three models were further tested on the Metz dataset [21]. The results obtained
for RFR were R 0.769 (0.759, 0.779), ρ 0.669 (0.659, 0.679), RMSE 0.504 (0.495, 0.513),
Concordance Index 0.749 (0.744, 0.755), and AUC 0.938 (0.930, 0.946). For XGBoost, R
0.667 (0.656, 0.679), ρ 0.574 (0.563, 0.585), RMSE 0.582 (0.574, 0.591), Concordance Index
0.703 (0.698, 0.709), and AUC 0.922 (0.913, 0.931) and and for ANN, R 0.60 (0.592, 0.608),
ρ 0.498 (0.489, 0.507), RMSE 0.619(0.612,0.627), Con. Index 0.658 (0.651, 0.665), and AUC
0.887 (0.880, 0.894). All the metrics were computed with a 95% confidence interval. Model
performance on an external set was some what low compared to the model performance on
the test set, but AUC showed a promising result for RFR and XGBoost for both the test
and external set. A threshold 7.55 (pKi value) was used for the Metz data as suggested
by Pahikkala et al. [25]. The comparison of evaluated scores on Metz dataset for three
different models is shown in Figure 4.5(a). Figure 4.5(b) shows the predictions of RFR
against actual values on Metz dataset.
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Figure 4.5: Metz dataset Results (a) Comparison of performance of models (left)(b) Predictions from Random forest against actual values (right)
Table 4.2: Performance of RF model on the test and Metz datasets
Metrics

Random Forest
Test dataset (95%)

R

0.887 (0.881, 0.893)

0.769 (0.759, 0.779)

ρ

0.846 (0.840, 0.853)

0.669 (0.659, 0.679)

RMSE

0.475 (0.465, 0.486)

0.504 (0.495, 0.513)

0.854 (0.851, 0.858)

0.749 (0.744, 0.755)

0.957 (0.954, 0.960)

0.938 (0.930, 0.946)

Con. Index
AUC

4.4.3

Metz dataset (95%)

Grid search vs random search

Hyperparameter optimization is considered to be the most challenging aspect of for any
model development. The main puropose here is to find a set of hyperparameters which
will lead to high precision and accuracy. Random forest was tuned by both grid search,
and random search methods, and we compared the performance of the model. In a grid
search, a combination of hyperparameters are first used for tuning the model and then the
combination which gives the best results results are chosen; whereas in the random search
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Table 4.3: Performance of XGBoost on the test and Metz datasets
Metrics

XGBoost
Test dataset (95%)

Metz dataset (95%)

R

0.862 (0.855, 0.868)

0.667 (0.656, 0.679)

ρ

0.795 (0.788, 0.802)

0.574(0.563, 0.585)

RMSE

0.522 (0.512, 0.533)

0.582 (0.574, 0.591)

0.805 (0.801, 0.810)

0.703 (0.698, 0.709)

0.946 (0.943, 0.950)

0.922 (0.913, 0.931)

Con. Index
AUC

Table 4.4: Performance of ANN on the test and Metz datasets
Metrics

Artificial neural network
Test dataset (95%)

Metz dataset (95%)

R

0.798 (0.794, 0.803)

0.60 (0.592, 0.608)

ρ

0.716 (0.710, 0.722)

0.498 (0.489, 0.507)

RMSE

0.631 (0.623, 0.639)

0.619 (0.612, 0.627)

0.779 (0.774, 0.784)

0.658 (0.651, 0.665)

0.933 (0.926, 0.940)

0.887 (0.880, 0.894)

Con. Index
AUC

method [2], a distribution of hyperparameters are provided and the values are randomly
picked on each iteration to train the model. It was more generally a process of choosing a
representative sample of the parameter from the entire space to understand all the data.
We used three hyperparameters, namely n estimators, max features, and min sample split
for RFR to optimize the model based on both grid search and random search as shown in
Table 4.5. The model performance was nearly the same for both the methods. However,
the model development time was significantly less for random search. This indicates that
random search gave similar results in a fraction of the time taken by grid search method.
We also observed a change in R and RMSE in accordance with an increasing the number of
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trees in RFR, yet it was found insignificant. It instead increased model development time.
The performance of RFR model by the grid search method and random search method is
shown in Table 4.6 and Table 4.7 shows the changes in R and RMSE on increasing the
number of trees in the RFR model.
Table 4.5: Hyperparameters tuning for RFR based on grid search and random search

Parameters

Grid Search

Range

Random Search

(best comb.) (best comb.)
[50, 100, 200, 400,

n estimators

600

600

600,800, 1000]
max features

[`auto’, `sqrt’, `log2’, None]

min sample split

`auto’

None

2

2

[2, 5, 10]

Table 4.6: Comparison of random search and grid Search
Random Search

Grid Search

EvaluationMetrics
Test set Metz set Test set Metz set
Pearson

0.887

0.769

0.887

0.769

Spearman

0.845

0.667

0.846

0.669

RMSE

0.475

0.504

0.475

0.504

Concordance Index 0.850

0.740

0.854

0.749

AUC

0.937

0.957

0.938

0.946
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Table 4.7: Change in R and RMSE on increasing the the number of trees for the test set
Number of trees R

4.4.4

RMSE

50

0.8829 0.4826

100

0.8865 0.4764

200

0.8871 0.4753

400

0.8874 0.4748

600

0.8876 0.4745

800

0.8871 0.4753

1000

0.8873 0.4751

Implementation

The model is available at https://drugdiscovery.utep.edu/pki/. The web interface takes
SMILES pattern and protein sequence as input and provides the predicted results. A
Docker image is also available as sirimullalab/kinasepkipred through Docker Hub.

4.5

Conclusion

A predictive model to estimate the inhibitor constant(pKi ) values of ligands against kinases
was developed. Three different ML algorithms were employed and evaluated using a blind
test set as well as an independent external set. Out of three models [random forest regressor,
extreme gradient boosting (XGBoost), and artificial neural network (ANN)], RFR gave
superior results for our drug-target pKi prediction. Also, a performance test on a grid
search and random search was performed, and our results indicated that both methods
yielded similar performance. Our best model, which is based on RFR, yielded Pearson R
values of 0.887(0.881, 0.893) and 0.769(0.759, 0.779) with 95% confindence interval on the
test and Metz datasets, respectively.
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4.6

Availability of data

The training/test and external test datasets are available on a GitHub repository https:
//github.com/sirimullalab/KinasepKipred, which also contains the source code of the KinasepKipred.
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Chapter 5
openDMPK: A suite of in silico tools
for drug metabolism and
pharmacokinetic properties
This chapter is adopted from: Govinda KC, Mahmudulla Hassan, and suman sirimulla.
”openDMPK: A suite of in silico tools for drug metabolism and pharmacokinetic properties”. (not submitted yet)

Abstract: openDMPK is a suite of in silico tools for prediction of drug metabolism and
pharmacokinetic properties. Drug Metabolism and Pharmacokinetic (DMPK) properties
assessment is a crucial step in the drug development process. In order to be an effective drug, it must not only have good specificity and potency in binding to the desired
target, but also maintain suitable in vivo gastrointestinal absorption, tissue distribution,
metabolic fate, and a benign toxicology profile. Thanks to modern technology, such as highthroughput robotics, detection systems, and specialized cell lines, laboratory PK screening
is becoming faster and cheaper than ever. Nevertheless, there is still a large overhead cost
to laboratory screening. Traditional computational methods used for PK property prediction, such as single-target QSAR, and multi-target QSAR were able to predict these
properties with varying degrees of success. In recent years, new machine learning methods have provided promising results in the prediction of some chemical properties, such as
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binding affinity, but the application of these methods to PK property prediction has been
hindered by the lack of high quality, publicly accessible datasets. Here we present a project,
where we provide free access to curated datasets of DMPK data and computational tools to
predict various DMPK properties that are developed based on cutting edge machine learning techniques. Three machine learning models [Random Forest (RFR), Extreme Gradient
Boosting (XGB) and Multi-layer Perceptron (MLP)] were tested for model development.
The performance of our models were evaluated using several metrics and best models were
selected based on the evaluated scores on test datasets and used for web implementation.

5.1

Introduction

The drug approval rate has risen faster in the past few decades, according to the US
Food and Drug Administration (FDA). The average annual number of new approvals of
medicines, including biologics, was 34 between 1990 and 1999, 25 between 2000 and 2009,
and 41 between 2010 and 2018 [1]. While this indicates that the number of approved drugs
has risen, they depend on a smaller number of data that raises the uncertainty of the efficacy of the medication at the time of approval [2]. That demonstrates that there are many
problems that are underestimated, while advanced technologies have helped to speed up
the process. The effectiveness and safety of the drug, mainly related to the properties of
absorption, delivery, metabolism and excretion (ADME) and different toxicities (T) and
these compound properties, need to be tested earlier in the discovery process. A drug
is an effective drug when it reaches a target inside the body at sufficient concentration
and stays for the required amount of time [3]. A good drug candidate should be potent
against the drug target to induce some biological response, highly selective, has good ADMET/pharmacokinetic properties, and so on. Druglike analysis is useful to discriminate
good drug candidates from the screening compounds. The most famous druglike filter is
the “Rule of 5” suggested by Lipinski [4], which states that a good drug candidate should
have molecular weight smaller than 500, the calculated logP (ClogP) smaller than 5.0, and
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the numbers of hydrogen bond donors and acceptors less than 5 and 10, respectively [5].
Although most drugs obey the four rules of the filter, “Rule of five” is only the minimum
criterion of a molecule to be druglike. It is very easy for a compound to fall within the
“Rule of five” but has no potential to become a drug. A huge range of molecular structures
are tested according to very varied requirements during the time- and resource-consuming
phases of drug research and production, in order to direct the collection of chemicals to
synthesize, analyze and facilitate, with the end aim of finding those with the best chance of
becoming a successful medication for patients. [3]. High biological activity and low toxicity
must be demonstrated by the molecules. ADMET properties are important to understand
the pharmacokinetic and drug metabolic properties that are useful in determining whether
a drug molecule will get to the target protein in the body and how long it stays in the
bloodstream. Early estimation of ADME in the discovery phase reduces drastically the
fraction of pharmacokinetics-related failure in the clinical phases [3]. Having a soluble
molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation [6]. In addition, solubility is a major property affecting absorption
for drug discovery targeting oral administration. A medication intended for parenteral use
must be strongly soluble in water in order to provide an adequate amount of the active
ingredient in the limited quantity of the prescription dose [6, 7]. Awareness of compounds
that are substrate or non-substrate of glycoprotein permeability is important for assessing
active efflux via biological membranes, such as from the gastrointestinal wall to the lumen
or from the brain [3, 8].
We created a web platform called openDMPK based on a comprehensively collected database that incorporates as many as possible existing ADMET and basic
physicochemical-related endpoints to facilitate the ADMET evaluation.

These quali-

fied ML models will be implemented in a user-friendly, publicly accessible web interface
(https:/drugdiscovery.utep.edu/opendmpk/) and are recommended as a valuable tool for
drug chemists in the drug discovery phase.
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Figure 5.1: Sunburst plot showing the distribution of openDMPK models

5.2
5.2.1

Method
Data sources

The openDMPK data collection was composed of two sections. Data for approximately half
of the total number of models were collected using manual filtering and processing references
[5, 9–17] given in admetSAR [18] supporting information. Metrabase [19], which is a small
molecule metabolism and transporter database, and a literature search using keywords
such as “transporter”, “volume distribution”, “Drug Induced Liver Effects” or “ADME/T
Tools” etc., collected the data for the remaining models.
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5.2.2

Data preparation

In the data collection process, a total of 51 datsets for the ADMET modeling were obtained.
Before data are amenable for modeling, some data preparation steps have to be performed.
Some of the datasets were pre-split as train, test and validation sets. However, most of them
were needed to be cleaned and split before fitting the ML models. Since data cleaning is the
most important part of machine learning model development, we have carefully worked on
data cleansing such as removal of duplicates, outliers, and those compounds which did not
produce chemical features. Duplicate compounds in regression models were consolidated
using median value when there were more than two cases of a compound and average value
for those had only two cases. Median values are better here than mean values, because they
are less influenced by outliers. For the classification data, only one entity was reserved if
there were two or more same compounds. All the SMILES were converted into their
Canonical form for the standardization purpose. The distribution of data for all trained
models are shown in Figure 5.2

Figure 5.2: Bar plot showing the data count for each model
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5.2.3

Descriptor Calculation

A total of 10 features that contained 8 from RDkit [20]: Avalon, extended connectivity
fingerprints (ECFP2, ECFP6), Molecular ACCess System (MACCS), rdkit Descriptors
(rdkDes), morgan, rdk5, and 3 from MayaChemTools [21]: topological pharmacophore atom
triplet fingerprint (TPATF), topological pharmacophore atom pair fingerprints (TPAPF),
and physicochemical properties (physc) were obtained. ECFP encode properties of atoms
and their neighbors into a bit vector of certain radius, feature type, and fold. The size
of fingerprints were 1024 for ECFPx (where, x=2 or 6), morgan (which is also known as
ECFP4): 1024, rdk5: 2048, MACCS: 167, rdkDes: 200, TPATF: 2692, TPAPF: 150, and
physc: 8.

5.2.4

Machine learning algorithms

In this study, three different machine learning algorithms: Random Forest [22], Extreme
Gradient Boosting (XGBoost) [23], Artificial neural network (ANN) [24], and were implemented and the best performing model was chosen for the web portal. However, a comparative study was also performed between the models trained with manually computed
molecular fingerprints and models trained on graph based neural networks that learns by
operating on graph structure of the molecule. For the details of various ML algorithms,
see chapter 1.

5.2.5

Evaluation Metrics

For all the models, we measured the accuracy, specificity, sensitivity, F1 score, Cohen’s
Kappa score and Mathew’s Correlation Coefficient (MCC), but to decide the best one, we
used the F1 score. The details about the evaluation metrics can be found in chapter 1.
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5.3
5.3.1

Results and Discussions
Model development

Machine learning models including RF, XGB, and MLP were used to build the models,
which were implemented by scikit-learn package with python scripts. Three-fold crossvalidation were employed to optimize the hyper-parameters such as the number of trees,
number of hidden layers etc. and the best model was selected according to their performance. Each of the three standard supervised learning algorithms was trained using a grid
search strategy for hyperparameter optimization. Models were trained and evaluated using
80% of the dataset for training and hyperparameter optimization and withholding 20% for
blind performance evaluation. Same training and test splits are for all the models. Data
was split based on stratified splitting making sure that 80% of positives or negatives are in
training and 20% positive or negatives are in test.
Out of 51 different models, XGB was found outperforming to other models as it showed
best performance in 19 among 51 trained ML models. RF performed better than MLP
with 17 best performing models (See Table 5.1, 5.2, and 5.3). Among the 10 different types
of features used, RDKit molecular descriptors was found outperforming to others.
In order to compare the model performances between the models trained with computed
molecular fingerprints and models trained on graph based neural networks that learns by
operating on graph structure of the molecule, we retrained the models using Chemprop.
The models were trained with 3-fold cross-validation (with different random number seeds).
The models were optimized using various model hyperparameters such as: hidden size of the
neural network layers, model’s depth, number of feed forward network layers, and dropout
probability. The DMPNN results are shown in Tables 5.4 and 5.5.
Based on the results obtained from traditional ML classifiers and D-MPNN, they showed
the similar performance in the case of classification problems while D-MPNN was showed
slightly better performance in regression models. The comparison of D-MPNN and best
models among others are in Figures (5.5, 5.6, 5.7).
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Figure 5.3: Scatter plots of scores obtained for classification models

Figure 5.4: Violin plot of scores obtained from classification models
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Figure 5.5: Comparison of scores of best models and Direct Message Passing Neural Network (DMPNN) (a) Accuracy (b) F1 score

Figure 5.6: Comparison of scores obtained from best models and Direct Message Passing
Neural Network (DMPNN) (a) Sensitivity (b) Specificity
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Figure 5.7: Comparison of scores obtained other models and DMPNN

Figure 5.8: Actual vs predicted values (a) Water solubility (b) Tetrahymena Pyriformis
Toxicity
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Figure 5.9: Actual vs predicted values (a) LOAE (b) CNS Permeability

5.4

Conclusion

In the present study, we have developed suite of ligand–based machine learning models for
drug metabolism and pharmacokinetic properties. Models were trained using four different
machine learning methods along with graph based neural networks. Among several trained
models, best performing models based on F1 score will be used for web implementation.
Based on the results obtained from traditional ML classifiers and D-MPNN, they showed
the similar performance in the case of classification problems while D-MPNN was showed
slightly better performance in regression models. Through this study we have also collected
data sets for various ADMET properties. In the future, we will continue to improve the
openDMPK as follows (i) additional models for ADMET properties should be added (ii)
The database should be updated regularly.

5.5

Implementation and Accessibility

openDMPK will be available online at https://drugdiscovery.utep.edu/opendmpk/v2.
All the codes and the trained models are available at https://github.com/sirimullalab/
opendmpk/.
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5.6

Appendix

Table 5.1: Results: Classification models
Type

Models Features AUC ACC F1

Ames

RF

MD

0.999

0.989

0.964 0.939 0.998 {7271, 729}

HOB

RF

MD

0.774

0.735

0.73

PgPiII

RF

MD

0.938

0.883

0.915 0.949 0.754 {736, 411}

DIE

XGB

MD

0.596

0.716

0.829 0.925 0.102 {696, 232}

CYP2C9s

RF

RDK

0.725

0.768

0.204 0.125 0.969 {501, 168}

PEPT1i

RF

RDK

0.77

0.932

0.965 1.0

HEPA

MLP

Avalon

0.709

0.716

0.811 0.932 0.312 {1628, 543}

CAT

RF

ECFP2

0.898

0.824

0.803 0.797 0.846 {659, 165}

HIA

XGB

MD

0.917

0.925

0.955 0.99

Caco-2

RF

MD

0.9

0.83

0.816 0.836 0.824 {529, 135}

MRP2s

XGB

TPAPF

0.897

0.862

0.87

OCT2

RF

MD

0.802

0.785

0.564 0.517 0.883 {668, 223}

PgPs

RF

MACCS

0.877

0.858

0.894 0.96

OCT1s

RF

MD

0.953

0.912

0.94

HBT

XGB

MD

0.84

0.812

0.769 0.789 0.828 {142, 48}

OATP2B1i XGB

Avalon

0.759

0.73

0.655 0.655 0.778 {222, 74}

MRP2i

MLP

MD

0.702

0.696

0.764 0.85

EC

XGB

RDK

0.983

0.957

0.943 0.967 0.95

PEPT1s

XGB

ECFP2

0.765

0.825

0.9

CYP2D6s

MLP

ECFP2

0.745

0.814

0.587 0.468 0.95

FAT

MLP

ECFP6

0.9

0.849

0.899 0.969 0.581 {415, 139}

BCRP1s

XGB

MD

0.885

0.827

0.853 0.932 0.706 {330, 110}

PgPsII

XGB

RDK

0.964

0.944

0.944 0.938 0.95
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SE

SP

Data Info

0.712 0.758 {746, 249}

0.167 {219, 74}

0.667 {360, 120}

0.909 0.812 {194, 65}

0.689 {212, 120}

0.929 0.867 {168, 57}

1.0

0.483 {205, 69}
{1724, 575}

0.176 {238, 80}
{500, 167}

{900, 484}

MN

XGB

Avalon

0.97

0.923

0.909 0.926 0.921 {576, 65}

AT

XGB

ECFP6

0.728

0.87

0.6

BBB

RF

TPATF

0.976

0.952

0.874 0.792 0.995 {1378, 460}

BCRP1i

XGB

MACCS

0.962

0.986

0.993 1.0

BIO

MLP

RDK

0.846

0.823

0.748 0.694 0.902 {1440, 164}

OATP1B1s XGB

Avalon

0.778

0.879

0.917 0.957 0.7

OATP1B1i XGB

ECFP2

0.76

0.909

0.95

PgPi

RF

MD

0.933

0.886

0.918 0.925 0.799 {1446, 482}

HEG

RF

MD

0.825

0.86

0.917 0.968 0.426 {927, 235}

MRP1S

MLP

ECFP2

0.95

0.956

0.958 0.958 0.952 {133, 45}

CYP3A4s

RF

ECFP6

0.65

0.607

0.656 0.808 0.433 {502, 168}

EI

XGB

MD

0.983

0.952

0.969 0.981 0.868 {3905, 1302}

0.462 0.979 {451, 123}

1.0

0.333 {418, 140}

{96, 33}

0.333 {264, 88}

Table 5.2: Results: Regression models
Type

Models R2

R

Rho

TPT

XGB

0.842 0.918 0.925 0.432 {1178, 393}

PPB

XGB

0.721 0.851 0.78

VD

XGB

0.512 0.716 0.684 0.44

WS

XGB

0.859 0.928 0.918 0.762 {987, 330}

CNS

RF

0.65

0.812 0.78

rmse Data Info

0.166 {1370, 457}
{455, 152}

0.365 {239, 80}

LOAE RF

0.565 0.755 0.729 0.629 {414, 139}

TC

0.499 0.72

RF

0.686 0.263 {389, 102}

Table 5.3: Results: Multiclassification model
Type Model Precision Recall F1
Carc

RF

0.763

0.761
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ACC Data Info

0.750 0.761

{661, 87, 161}

Table 5.4: DMPNN Results: Classification models
Type

AUC ACC F1 score SE

AMES

0.948 0.926 0.956

0.967 0.967 0.707

AT

0.839 0.846 0.486

0.346 0.346 0.979

BBB

0.953 0.921 0.95

0.965 0.965 0.762

BCPR1i

0.927 0.973 0.986

1.0

BIO

0.846 0.823 0.734

0.645 0.645 0.931

CAT

0.9

0.757 0.757 0.868

CYP1A2i

0.844 0.683 0.68

0.539 0.539 0.924

CYP2C19i

0.849 0.791 0.624

0.648 0.648 0.843

CYP2C9i

0.866 0.817 0.64

0.686 0.686 0.858

CYP2C9s

0.64

0.754 0.327

0.286 0.286 0.877

CYP2D6i

0.897 0.871 0.653

0.638 0.638 0.926

CYP2D6s

0.734 0.679 0.442

0.447 0.447 0.771

CYP3A4i

0.804 0.755 0.613

0.657 0.657 0.796

CYP3A4s

0.708 0.597 0.707

0.915 0.915 0.238

Caco-2

0.855 0.778 0.762

0.787 0.787 0.77

DIE

0.589 0.668 0.777

0.85

EC

0.987 0.939 0.921

0.927 0.927 0.947

EI

0.972 0.943 0.962

0.968 0.968 0.874

FAT

0.931 0.856 0.892

0.904 0.904 0.763

HBT

0.829 0.718 0.703

0.65

HEG

0.783 0.847 0.91

0.968 0.968 0.362

HEPA

0.714 0.678 0.751

0.733 0.733 0.571

HIA

0.987 0.938 0.964

1.0

HOB

0.734 0.633 0.622

0.588 0.588 0.68

0.818 0.789
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SE

1.0

0.85

0.65

1.0

SP

0.0

0.283

0.789

0.6

MN

0.971 0.938 0.929

0.963 0.963 0.921

MRP1S

0.833 0.75

0.947 0.947 0.529

MRP2i

0.709 0.643 0.63

0.567 0.567 0.731

MRP2s

0.842 0.75

0.607 0.607 0.917

0.8

0.723

OATP1B1i 0.683 0.901 0.948

1.0

OATP1B1s 0.301 0.231 0.091

0.053 0.053 0.714

OATP1B3i 0.592 0.817 0.899

0.98

0.98

0.0

OATP2B1i 0.713 0.667 0.63

0.68

0.68

0.657

OCT1i

0.743 0.833 0.909

0.982 0.982 0.0

OCT1s

0.725 0.717 0.794

0.806 0.806 0.533

OCT2

0.712 0.696 0.466

0.49

0.49

0.773

PEPT1i

0.681 0.915 0.956

1.0

1.0

0.0

PEPT1s

0.668 0.781 0.86

0.915 0.915 0.412

PGPiI

0.877 0.822 0.874

0.938 0.938 0.595

PGPiII

0.723 0.657 0.72

0.663 0.663 0.645

PGPsI

0.831 0.758 0.824

0.907 0.907 0.511

PGPsII

0.873 0.833 0.845

0.905 0.905 0.759
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1.0

0.0

Table 5.5: DMPNN Results: Regression models
Type

Rˆ2

R

Rho

rmse

CNS

0.486 0.706 0.717 0.469

FS

0.915 0.96

LIP

0.729 0.856 0.876 0.639

0.969 1.105

LOAE 0.469 0.685 0.636 0.726
PPB

0.747 0.867 0.826 0.166

TC

0.432 0.675 0.658 0.28

TPT

0.868 0.932 0.929 0.373

VD

0.539 0.742 0.752 0.42

WS I

0.897 0.947 0.947 0.63

WS II 0.888 0.944 0.936 0.633
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Chapter 6
Conclusion
In this dissertation, I investigated various machine learning (ML) algorithms including
graph based neural networks to compare and improve state of art algorithms for the molecular property prediction. I gathered a large collection of publicly available experimental
data which were used to fit the various machine learning models. Among various ML algorithms, MLP, XGB, and RF were found outperforming to other ML algorithms. Graph
based neural networks slightly performed better only in the case of regression models. However, it had comparable performance in classification models. Trained models are deployed
and made accessible online to scientific communities working in drug discovery research.
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Chapter 7
Future work
However, this dissertation covered the various machine learning methods for predicting
the molecular properties and resulted in web-based tools, one additional factor to consider
while developing such tools is the so-called applicability domain (AD). The in–silico model
is limiting and can only be assumed to make accurate predictions for the small number
of chemicals that are structurally identical to compounds set for training. Based on how
close it is to the training compounds used in model development, the AD analysis makes it
possible to quantify the uncertainty in the estimation of a given molecule. Therefore, AD
implementation for each project may be another crucial task that needs to be undertaken.
In addition, many chapters include specific directions for future work, such as (i)
openDMPK can be expanded further by introducing more realistic models for new ADMET
properties and periodically updating the database (ii) integrating new NCATS assays such
as In vitro Infectivity and Human Cell Toxicity in REDIAL2020.
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